

CURRICULUM VITAE

Alan Thomas Remaley, M.D., Ph.D.

National Institutes of Health

Bldg. 10/Rm. 2C-433

10 Center Drive

Bethesda, MD. 20892

Tel: (301) 219-9233

Fax: (301)-402-1885

aremaley1@nhlbi.nih.gov

Education:

- | | | |
|-----------|----|--|
| 1977-1981 | -- | B.S., Biochemistry and Chemistry
University of Pittsburgh, Pittsburgh, PA |
| 1981-1985 | -- | Ph.D., Biochemistry
University of Pittsburgh School of Medicine, Pittsburgh, PA |
| 1981-1987 | -- | M.D., University of Pittsburgh School of Medicine, Pittsburgh, PA |

Postgraduate Training:

- | | | |
|-----------|----|---|
| 1987-1990 | -- | Resident in Clinical Pathology, Division of Laboratory Medicine,
Department of Pathology and Laboratory Medicine,
University of Pennsylvania School of Medicine, Philadelphia, PA |
| 1990-1993 | -- | Medical Staff Fellow, Public Health Service, National Institutes of
Health, National Heart, Lung and Blood Institute, Molecular Disease
Branch, Bethesda, MD |
| 1993-1995 | | Senior Staff Fellow, Public Health Service, National Institutes of
Health, National Heart, Lung and Blood Institute, Molecular Disease
Branch, Bethesda, MD |

Academic Positions:

- | | | |
|--------------|----|---|
| 2013-present | -- | Senior Investigator, Section Chief, Lipoprotein Metabolism Section, Cardiopulmonary
Branch, NHLBI, National Institutes of Health, Bethesda, MD |
| 2008-2013 | -- | Investigator, Section Chief, Lipoprotein Metabolism Section, Cardiopulmonary Branch,
NHLBI, National Institutes of Health, Bethesda, MD |
| 2011-present | -- | Senior Staff/Public Health Service, Department of Laboratory Medicine, Director of
Special Chemistry Laboratory, Clinical Center, National Institutes of Health,
Bethesda, MD |
| 1997-2014 | -- | Senior Staff/Public Health Service, Department of Laboratory Medicine, Director of
Immunoassay Laboratory, Clinical Center, National Institutes of Health, Bethesda,
MD |

- 2009-2011 -- Senior Staff/Public Health Service, Department of Laboratory Medicine, Director of Mass Spec/HPLC Laboratory, Clinical Center, National Institutes of Health, Bethesda, MD
- 2001-2006 -- Senior Staff/Public Health Service, Department of Laboratory Medicine, Director of HIV Viral Load Laboratory, Clinical Center, National Institutes of Health, Bethesda, MD
- 1995-1997 -- Senior Staff/Public Health Service, Department of Laboratory Medicine, Director of General Chemistry Laboratory, Clinical Center, National Institutes of Health, Bethesda, MD

Research Training Experience:

- 1980-1981 -- Undergraduate Research: Department of Biochemistry, University of Pittsburgh, Subject: Biochemistry of secondary metabolism of *Penicillium brevicompactum*. Mentor: Dr. Ian M. Campbell
- 1983-1985 -- Doctoral Research: Department of Biochemistry, University of Pittsburgh School of Medicine, Subject: Purification and characterization of membrane-bound acid phosphatase of *Leishmania donovani* and its interaction with host defense mechanisms. Mentor: Dr. Robert H. Glew
- 1989-1990 -- Post Doctoral Research: Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Subject: Molecular biology and cell biology of the glycosylation of rabies virus glycoprotein and glycoporphin. Mentor: Dr. Steven L. Spitalnik
- 1990-1995 -- NIH Research Fellowship/ Public Health Service: National Institutes of Health, National Heart, Lung, and Blood Institute, Molecular Disease Branch, Subject: 1) Cholesterol-regulated gene expression, 2) Apolipoprotein biosynthesis and secretion. Mentor: Dr. H. Bryan Brewer.

Teaching Experience:

- 1981 -- Teaching Assistant, Algebra, Trigonometry and Geometry, Department of Mathematics, University of Pittsburgh
- 1987 -- Assistant Instructor, Pathology-100, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine
- 1988-1990 -- Assistant Instructor, Pathology-300, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine
- 1998 -- FAES Instructor, Clinical Chemistry course, National Institutes of Health, Bethesda, MD
- 2002-2005 -- Guest Lecturer in Biochemistry, USUHS Medical School, Bethesda, MD

Professional Licensure and Boards:

- 1987 -- National Board of Medical Examiners
- 1988 -- Medical License, Pennsylvania
- 1992 -- American Board of Pathology, Clinical Pathology

Awards and Honors:

2016	--	NHLBI Director's Award, AHA
2015	--	ATVB Special Recognition Award, AHA
2013	--	NIH Director's Award, NIH
2013	--	ATVB Journal Reviewer Award, ATVB
2012	--	Cooper Award, Lipoprotein and Vascular Disease Division, AACC
2012	--	Orloff Science Award, (co-recipient for Parkin Function), NHLBI, NIH
2012	--	Orloff Science Award, (co-recipient for Peptide-Asthma), NHLBI, NIH
2009	--	FDA Leveraging/Collaboration Award, FDA
2008	--	Merit Award, National Human Genome Research Institute, NIH
2007	--	Outstanding Unit Citation Award, Public Health Service
2007	--	Clinical Center Director's Patient Care Award, Clinical Center, NIH
2007	--	Advisory Committee Service Award, FDA
2007	--	Best Article Award, Lipoprotein and Vascular Disease Newsletter, AACC
2006	--	Crisis Response Service Award, Public Health Service
2006	--	Past-Chair Award, Capital Section, AACC
2005	--	Citation Award, Public Health Service
2005	--	Clinical Center Director's Science Award, Clinical Center, NIH
2004	--	Past-Chair Lipoprotein and Vascular Disease Division Award, AACC
2003	--	Promoted to Captain, US Public Health Service
2001	--	Commendation Medal, Public Health Service
2001	--	Zak Award for Lipoprotein Research, Amer. Assoc. Clin. Chem.
2000	--	Commendation Medal, Public Health Service
1998	--	Bicentennial Unit Commendation Medal, Public Health Service
1996	--	Arteriosclerosis fellow in American Heart Association
1995	--	Young Investigator Award, American Assoc. Clinical Chemistry
1995	--	Lipoprotein Research Poster Award, Amer. Assoc. Clinical Chemistry
1994	--	Promoted to Commander, US Public Health Service
1993	--	Young Investigator Award, Acad. Clin. Lab. Physicians and Scientists
1992	--	Diplomate, American Board of Pathology (Clinical Pathology)
1991	--	Promoted to Lieutenant Commander, US Public Health Service
1990	--	Commissioned as Lieutenant, US Public Health Service
1989	--	Postdoctoral Fellowship Award, NIH (CA09140-15)
1988	--	Diplomate, National Board of Medical Examiners
1987	--	Brinton Prize for Academic Performance, Univ. Pitt. Medical School
1986	--	University Scholar Award, University of Pittsburgh
1986	--	Eli Goldstein Award for Academic Performance, Univ. Pitt Medical School
1986	--	AOA Honorary Society, University of Pittsburgh School of Medicine
1985	--	Culpeper Foundation Fellow Research Award
1983	--	Dean's Scholarship Award of the University of Pittsburgh
1981	--	Sigma Chi Scientific Junior Honorary Society
1981	--	Graduated with B.S. <i>Summa Cum Laude</i> , University of Pittsburgh
1981	--	University Scholar Award, University of Pittsburgh
1980	--	University Scholar Award, University of Pittsburgh
1978	--	Phi Eta Sigma Honorary Society, University of Pittsburgh
1978	--	Tri Beta Biological Honorary Award, University of Pittsburgh
1977	--	Westinghouse Science Scholarship Honors Group Award

Current and Past Boards and Other Positions:

2017	--	Board of Directors, National Lipid Association
2016	--	Co-Chair, NIH-CC/FDA-CDER Task Force for Clinical Trials
2016	--	AHA writing group member on "Prescription Dose of Omega-3 Fatty Acids for Triglyceride Lowering". AHA
2016	--	Co-Chair, Gordon Conference-Lipoprotein meeting in 2018
2015	--	ATVB Leadership Committee Council, AHA

2015	--	Ad Hoc Reviewer, Atherosclerosis and Inflammation of the Cardiovascular System Study Section, NHLBI, NIH
2010-present	--	Proteomic Core User Committee member, NHLBI, NIH
2014	--	Trans-NIH Earl Stadtman Fellow Selection Committee, NIH
2014	--	Chair, SouthEast Lipid Research Conference, Atlanta, GA
2013-present	--	Laboratory Medicine Best Practices Expert Panel for Cardiovascular Biomarkers, Center of Analytics and Public Health, CDC, Atlanta, GA
2013	--	Vice-Chair, SouthEast Lipid Research Conference, Atlanta, GA
2013-present	--	Scientific Advisory Board Member, Global Genomics Group Study, Health Diagnostic Laboratory, Richmond, VA
2013-present	--	Clinical Investigators Working Group, NHLBI, NIH
2013	--	Co-Chair, HDL Satellite meeting for ATVB, AHA
2012-present	--	Chair, American Heart Association Grant Committee-Clinical Study Section
2012-present	--	Committee Member, NIH-CC/FDA-CDER Task Force for Clinical Trials
2012-present	--	Committee Member on Proficiency Testing for clinical laboratories, Clinical and Laboratory Standards Institute (CLSI), Wayne, PA
2012	--	Co-Chair, HDL Satellite meeting for ATVB, AHA
2011	--	Ad Hoc Reviewer, Atherosclerosis and Inflammation of the Cardiovascular System Study Section, NHLBI, NIH
2011-present	--	Advisory Board Member for Clinical Chemistry and Clinical Toxicology Device Panel, FDA
2011	--	Committee Member for Cardiovascular Risk Marker Panel National Lipid Association
2010-present	--	Vice Chair, General Chemistry Proficiency Testing Committee, College of American Pathologists
2010-present	--	Animal Imaging Core Committee, NHLBI, NIH
2010-2012	--	Chair, Laboratory of Animal Medicine and Surgery Users Committee, NHLBI, NIH
2009-2011	--	Vice-Chair, AHA National Level Grant Review Committee
2008-2011	--	Advisory Board Member for Proficiency Testing (General Chemistry Committee), College of American Pathologist
2008-present	--	Committee Member of Technology Evaluation Advisory Committee, NHLBI, NIH.
2007-2011	--	Cardiovascular Biomarker Standardization Steering Committee, CDC
2006	--	Cardiovascular Biomarker Committee, NHLBI
2006-present	--	Loan Repayment Committee Review member, National Inst. of Health
2006-2007	--	Chair of Capital Section Division, AACC
2005-2007	--	Advisory Board Member for Proficiency Testing (Special Chemistry Committee), College of American Pathologists
2004	--	Promotion Board, <i>US Public Health Service</i>
2002-present	--	Advisory Board Member for Clinical Chemistry and Clinical Toxicology Device Panel, Food and Drug Administration
2004-2005	--	Practice Guideline Committee Member for PTH Testing for Parathyroid Cancer, National Academy of Clinical Biochemistry
2004-2005	--	Member of National Forum for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention
2004-2005	--	Practice Guideline Committee Member for Intraoperative PTH Testing, National Academy of Clinical Biochemistry
2002-2003	--	Chair of the Lipoprotein and Vascular Disease Division, AACC
2001-2003	--	Institutional Review Board Member, National Institute of Child Health and Development, NIH
2001-2003	--	Continuing Medical Education Committee Member, AACC
1999-2003	--	Grant Review Committee Member (Mid-Atlantic Region), American Heart Association

Editorial Board Positions:

2015-present	--	Associate Editor, Journal of Clinical Lipidology
2014-present	--	Editorial Board, Journal Geriatric Cardiology
2013-present	--	Editorial Board, Cardiovascular Pharmacology
2012-present	--	Editorial Board, Arteriosclerosis, Thrombosis, and Vascular Biology
2011-present	--	Editorial Board, Journal of Lipid Research

2010-present	--	Editorial Board, Journal of Immunology, Endocrinology & Metabolic Agents in Medicinal Chemistry
2009-present	--	Editorial Board, Journal of Pediatric Biochemistry
2008-present	--	Editorial Board Member, <i>Open Atherosclerosis and Thrombosis Journal</i>
2008-2010	--	Section Editor, <i>Clinical Chemistry</i> journal
2005-present	--	Editorial Board Member, <i>Clinical Laboratory News</i> , AACC
2005-2010	--	Editorial Board Member, <i>Atherosclerosis</i>
2005-present	--	Editorial Board, <i>Lipoprotein and Vascular Biology Newsletter</i> , AACC
2004-present	--	Editorial Board, <i>Clinical Chemistry</i> journal

Professional Societies:

1987-present	--	American Association of Clinical Chemistry (AACC)
1990-1995	--	Mid-Atlantic Lipid Club Society
2004-present	--	College of American Pathologists
2007-present	--	American Heart Association
2007-present	--	National Lipid Association

Trainees:

Post-doctoral Fellows (NHLBI)

2015-Present	--	Anna Wolska, PhD, Post-doctoral fellow, NHLBI
2014-Present	--	Zhihong Yang, PhD, Post-doctoral fellow, NHLBI
2012-Present	--	Scott Gordon, PhD, Post-doctoral fellow, NHLBI
2012-2013	--	Lusana Ahsan, MD, Medical Research Scholars Program, NHLBI (Post-employment position: Medical student, NYU)
2008-2012	--	Kasey Vickers, PhD, Post-doctoral fellow, NHLBI (Post-employment position: Asst. Prof. Vanderbilt Univ.)
2011-Present	--	Seth Thacker, PhD, Post-doctoral fellow, NHLBI (Post-employment position: Post-doctoral Fellow, FDA)
2009-2011	--	Denis Sviridov, MD, PhD Post-doctoral fellow, NHLBI (Post-employment position: Staff Scientist, NIH)
2007-2011	--	Yoshitaka Sekine, MD, Post-doctoral fellow, NHLBI (Post-employment position: Asst. Prof. Gunma Univ., Japan)
2007-2011	--	Xavier Rousset, PhD, Post-doctoral fellow, NHLBI (Post-employment position Post-doctoral fellow, Univ. J. Fourier)
2006-2010	--	Amar Sethi, MD, PhD, Post-doctoral fellow, NHLBI (Post-employment position: Chief Scientific Officer Pacific Biomarkers)

Graduate Students (NHLBI)

2016-Present	--	Rafique Islam, PhD student-NHLBI-George Mason Univ.
--------------	----	---

Post-Baccalaureate Students (NHLBI)

2013-2015	--	Abdul Zarzour, Pre-Irta student, NHLBI (Post-employment position: Medical residency, Univ. of Georgia)
2013-2015	--	Georgina Kemeh, Pre-Irta BRPTG student, NHLBI (Post-employment position: Research Technologists, Biorad)
2010-2012	--	Imoh Ikpot, Pre-Irta BRPTG student, NHLBI (Post-employment position: Medical student, Cooper Univ.)
2010-2012	--	David Osei, Pre-Irta BRPTG student, NHLBI (Post-employment position: MD, PhD student, Univ. Pittsburgh)
2010-2011	--	Bassem Shoucri, Pre-Irta student, NHLBI (Post-employment position: MD, PhD student, UC Davis)
2009-2010	--	Brian Palmisano, Pre-Irta student, NHLBI

2008-2010	--	(Post-employment position: MD, PhD student, Vanderbilt Univ.) Mona Ghias, Pre-Irta student, NHLBI
2008-2010	--	(Post-employment position: Medical student, St. Georges Univ.) Alonzo Jalan, Pre-Irta BRPTG student, NHLBI (Post-employment position: Medical student, Howard Univ.)

Clinical Chemistry Fellows (Clinical Center)

2015-2016	--	Kerry Welsh, MD, Clinical Chemistry fellow, CC (Post-employment position: Medical Officer, FDA)
2014-2016	--	Likhona Masika, MD, Clinical Chemistry fellow, CC (Post-employment position: Staff Pathologist, South Africa)
2012-2014	--	Verena Gourden, MD, Clinical Chemistry fellow, CC (Post-employment position: Assistant Professor, Univ. of Durban)
2011-2012	--	Marcelo Oliviera, MD, Clinical Chemistry fellow, CC (Post-employment position: Medical Health Consult., San Paola, Brazil)
2010-2011	--	Amar Sethi, MD, PhD, Clinical Chemistry fellow, CC (Post-employment position: Chief Scientific Officer Pacific Biomarkers)
2009-2010	--	Manuel Van Deventer, MD, Clinical Chemistry fellow, CC (Post-employment position: Staff Pathologist, Lancelot Lab)
2006-2009	--	Denis Sviridov, MD PhD, Clinical Chemistry fellow, CC (Post-employment position: Staff scientist NIH)
2004-2006	--	Raffick Bowen, PhD, Clinical Chemistry fellow, CC (Post-employment position: Asst. Professor, Stanford Univ.)
2002-2004	--	Joseph Wood, MD, Clinical Chemistry fellow, CC
2001-2002	--	Min Xu, MD, PhD, Clinical Chemistry fellow, CC (Post-employment position: Asst. Professor, Washington Univ.)
2000-2001	--	Jaelyn Hu, MD, PhD, Clinical Chemistry fellow, CC (Post-employment position: Staff Pathologist, WAMC, Fort Bragg)
1999-2000	--	Jayasimha Murthy, PhD, Clinical Chemistry fellow, CC (Post-employment position: Asst. Prof., Brown Alpert Medical School)
1999-2000	--	Ilka Warshavsky, MD PhD, Clinical Chemistry fellow, CC (Post-employment position: Staff Pathologist, Blood Center of Wisc.)
1997-1998	--	Yanyun Wu, MD, PhD, Clinical Chemistry fellow, CC (Post-employment position: Asst. Professor, Yale Univ.)
1995-1996	--	Elena Hristova, MD, Clinical Chemistry fellow, CC

Patents:

1. **Remaley, AT**, Ruddell M, Miller PC: Apparatus and method for kinetic analysis of the intraoperative assay for parathyroid hormone. Patent #A1513US, April 1999
2. DeLeo, J.M.; **Remaley, A.T.**: System and method for intelligent quality control of a process. Provisional Patent #17144762US, May 2000
3. Argraves, W.S.; Hammad, S.M.; Steffinson, S.; Brewer, H.B.; **Remaley, A.T.**: Method and Composition for HDL Holoparticle Uptake Receptor. Provisional Patent #60/085-556, June 1998.
4. **Remaley, AT**, Sampson ML, Cskao, G: A Dual HDL/Total cholesterol test. Provisional Patent #15280-393000US, May 2000
5. Deneffe P, Rosier M, Arnould-Reguigne E, Duverger N, Jaye M, Searfoss G, **Remaley AT**, Brewer HB, Dean M: Nucleic acid sequence of the human ABCA1 gene and the therapeutic and diagnostic application. Provisional Patent #99402668,0-2116, August 1999
6. **Remaley AT**, Brewer HB, Stonik JM, Demosky S, Thomas, F, Neufeld, E, Amar, M. Multi-Domain Ampipathic Helical Peptides and Methods of Their Use. Provisional Patent #E-114- 2004/0-US-01, October 2004

7. **Remaley AT**, Amar M. Hypertriglyceridemia from apoA-I and apoA-I mimetic peptides and new peptides to prevent. (E-138-2008) Converted to PCT.
8. **Remaley AT**, Sviridov D. New Synthetic apoA-I Mimetic Peptide with Specificity for Cholesterol Efflux (E-047-2009). Converted to PCT.
9. **Remaley AT**, Amar A, Sviridov D, Ikot II, Osei D. Chemical Modification of Apolipoprotein Mimetic Peptides for the Production of Therapeutic Agents. April 2011-Filed Provisional
10. Lacko, A, **Remaley AT**. Drug Delivery Vehicle. April 2012-Filed Provisional August 2012 (Patent # 611682,057)
11. Gordon SM, Remaley AT. Lipoprotein targeting protease inhibitors and uses. May 2016-Filed Provisional (Patent # 62/332.277)
12. Devarajala M, Lo, L, Soumitra G, Wolska A, Remaley AT. ApoC-II Mimetic Peptides. April 2016-Filed Provisional (Patent # 62/476,535)
13. Devarajala M, Lo, L, Soumitra G, Wolska A, Remaley AT. Methods of treating hypertriglyceridemia with apoC-II mimetic peptides. April 2016-Filed Provisional (Patent # 62/476,531)

Invited Lectures:

1. "ApoA-I Mimetic Peptides for Cholesterol Efflux by ABCA1" Solvo Biotechnology Transporter Conference, San Francisco, CA, April 2015
2. "HDL Structure and Function" UCSF, San Francisco, CA, April 2015
3. "ApoC-II Mimetic Peptides for Lowering Triglycerides" Peptide Drug Design & Delivery Summit, San Francisco, CA, April 2015
4. "Recombinant LCAT for Treatment of Familial LCAT Deficiency" American Society of Nephrology Meeting, Chicago, Ill. Nov. 2016
5. "ApoA-I Mimetic Peptides for Drug Delivery" Lipids-Nanotechnology Meeting, Tours, France, Sept. 2016,
6. "Diagnosis and Treatment of Hypertriglyceridemia" EFLM Meeting, Warsaw, Poland, Sept. 2016
7. "Recombinant LCAT for Treatment of Familial LCAT Deficiency" Chinese Heart Congress, Beijing, China, Aug. 2016
8. "Development of LCAT into a Therapy for Cardiovascular Disease" Univ. of Milan, Milan, Italy, Jun 2015
9. "Use of NMR for Lipoprotein Analysis and Cardiovascular Disease Risk Determination" EFLM/IFCC meeting, Paris, France, Jun 2015
10. "LCAT: Bench to Bedside" Univ. of Washington, Seattle Wash, Jun 2015
11. "Development of LCAT into a Therapy for Cardiovascular Disease" Univ. of Maryland, MD, April 2015
12. "Development of LCAT into a Therapy for Cardiovascular Disease" Vanderbilt Univ., Nashville, TN, April 2015

13. "Alternative CVD Biomarkers for LDL-C" European Atherosclerosis Biomarker Guideline Committee meeting, Glasgow, England, March 2014
14. "Measurement of High Density Lipoproteins" American Heart Association annual meeting, Chicago, IL, Nov 2014
15. "Development of LCAT into a Therapy for Cardiovascular Disease" Univ. of Kentucky, Lexington, KY, Oct 2014
16. "LCAT: Relationship to CVD and new therapies" Gordon Conference, Waterville, NH, Jun 2015
17. "High Density Lipoproteins: Update on Diagnostics and Therapeutics" American Society of Hypertension annual meeting, New York, NY, May 2014
18. "Apolipoprotein Mimetic Peptides" PEGS Annual meeting, Boston, MA, May 2014
19. "Development of LCAT into a Therapy for Cardiovascular Disease" Royal Hobart Hospital Cardiovascular Symposium, Hobart, Australia, July 2014
20. "Tangier Disease and other low HDL syndromes" Royal Hobart Hospital Cardiovascular Symposium, Hobart, Australia, July 2014
21. "LCAT and Cardiovascular Disease" International Atherosclerosis Society HDL meeting, Milan, Italy, March 2014
22. "Expanded Access/Single Patient IND for LCAT Therapy" NIH-FDA/CDER Joint Task Force Conference, Bethesda, MD, Dec 2013
23. "Biology of LCAT and its Development into a Novel Therapy for Cardiovascular Disease" SouthEast Research Lipid Conference Atlanta, GA, Sept 2013
24. "Development of novel therapies for increasing reverse cholesterol transport" USUHS Translational Medicine Seminar, Bethesda, MD, Nov 2013
25. "Role of miRNAs in cholesterol biosynthesis". SLOS Research Symposium, Pittsburgh, PA, June 2013
26. "Translating new findings HDL metabolism into novel therapies for cardiovascular disease" Dept. of Regenerative Medicine and Cell Biology, Medical Univ. of South Carolina, Charleston, SC, May 2013
27. "Translating new findings HDL metabolism into novel therapies for cardiovascular disease" Dept. of Pathology, Univ. of Minn., Minneapolis, MN, May 2013
28. "Development of recombinant LCAT: Phase I clinical trial results" ATVB meeting, Orlando, FL, April 2013
29. "Development of novel drugs for enhancing the Reverse Cholesterol Transport pathway" Dept. Pathology, Columbia Univ, New York, NY, Dec. 2012
30. "MiRNAs and Cardiovascular Disease" European Lipid Club Meeting, Munich, Germany, Sep. 2012
31. "ApoA-I Mimetic Peptides" Lovelace Respiratory Institute, Albuquerque, NM, Oct. 2012
32. "Lipids and Lipoprotein as Cardiovascular Biomarkers" American Association of Clinical Chemistry Meeting, Los Angeles, CA, July 2012
33. "Lipids and Lipoprotein Test Standardization" US-Japanese Standardization AACC Meeting, Los Angeles, CA, July 2012
34. "Genetic Dyslipidemias: Diagnosis and Treatment" American Association of Clinical Chemistry Meeting, Los Angeles, CA, July 2012

35. "HDL Biology and New Therapies" American Association of Clinical Chemistry/Lipoprotein Vascular Disease Meeting, Los Angeles, CA, July 2012
36. "ApoA-I Mimetic Peptides: Mechanism of Action" International Atherosclerosis Society Meeting, Sydney, Australia, Mar. 2012
37. "Recombinant LCAT as a Possible New Therapy for Cardiovascular Disease" International Atherosclerosis Society Satellite Meeting on New Therapies, Melbourne, Australia, Mar. 2012
38. "LCAT and SR-BI and the Effect of Free Cholesterol on Hematopoiesis and Atherosclerosis as a Possible New Therapy for Cardiovascular Disease" International Atherosclerosis Society Satellite Meeting on HDL Biology, Cannes, Australia, Mar. 2012
39. "MicroRNAs that Modulate Lipid Metabolism" Deuel Confernece, Palm Springs, CA, Mar. 2012
40. "New HDL Based Therapies for Cardiovascular Disease" Univ. of North Texas, Fort Worth, TX, Dec. 2011.
41. "Recombinant LCAT: Potential New Therapy for Cardiovascular Disease" Annual American Heart Association Meeting, Orland, Florida, Nov. 2011.
42. "New HDL Based Therapies for Cardiovascular Disease" Univ. of Alabama Cardiovascular Disease Meeting, Birmingham, Alabama, Sept. 2011.
43. "Multiple "Omic" Approach for Understanding Fatty Liver Disease" South Africa Clinical Chemistry Meeting, Johannesburg, South Africa, Aug. 2011.
44. "Biology of HDL and Cardiovascular Disease" Dept. Pathology, Dept. Univ Kwazulunatal, Durban, South Africa, Aug. 2011.
45. "Standardization of Lipid and Lipoprotein Testing" Japanese Atherosclerosis Society, Tokyo, Japan, Aug. 2011.
46. "Update on Cardiovascular Biomarkers". Amer. Assoc. Clinical Chemistry Annual meeting, Atlanta GA, July 2011
47. "LCAT and Hepatic Lipase: Anti and Pro-atherogenic Roles" 2nd HDL Summit Meeting, New York, NY, May. 2011.
48. "Structure Function Studies of Novel ApoA-I Mimetic Peptides" ATVB HDL Workshop, Chicago, ILL April 2011.
49. "Use of Lp(a) as a Cardiovascular Biomarker" National Lipid Association Biomarker meeting, Miami, Florida, Jan 2011.
50. "High Density Lipoproteins: Update from diagnostics to therapeutics" 37th Association of Clinical Biochemists of India, Mumbai, India, Dec 2010.
51. "Structure Function Studies of Apolipoprotein Mimetic Peptides" Sixth International Atherosclerosis HDL meeting, Vancouver, Canada, May 2010.
52. "Direct HDL-C Testing and Standardization" 1st HDL Summit Meeting, New York, NY, Jan. 2010.
53. "Evaluation of direct HDL-C and LDL-C Assays" Japanese Atherosclerosis Society, Shimonoseki, Japan, July 2009.
54. "5A bihelical peptide: Structure Function Studies" ATVB HDL workshop, Washington DC, April 2009.
55. "Diagnostic and therapeutic update of HDL" Univ. of Minnesota, Minneapolis, MN, January 2008.
56. "Translational Medicine in Lipoprotein Research" APEC conference, Taiwan, July 2008

57. "Design of ApoA-I mimetic peptides and their therapeutic effect" Merck Co., West Lake, NJ, January 2008.
58. "Update on HDL: From diagnostics to therapeutics". Amer. Assoc. Clinical Chemistry Annual meeting, San Diego CA, July 2007
59. "Development of rapid intraoperative endocrine assays for the surgical management of patients with endocrine tumors". Robert Wood Johnson Medical School, New Brunswick NJ, May 2007
60. "ApoA-I mimetic peptides and their effect on atherosclerosis". DALM Conference, New York NY, October 2007
61. "From Tangier disease to super HDL: A 40 year journey. Univ. of Alberta, Alberta Canada, March 2007
62. "LCAT deficiency: A link between atherosclerosis and renal disease" Royal Hobart Hospital, Hobart, Australia, Oct. 2006
63. "From Tangier disease to super HDL: A 40 year journey". Baker Heart Institute, Melbourne Australia, Oct. 2006
64. "HDL-C test standardization: Homogenous assays are they a step forward?" Joint meeting of Japanese and American Lipoprotein Standardization meeting. Chicago, IL, July 2006
65. "ABCA1 transporter and Tangier disease" Yale Univ. New Haven, CT, March 2006
66. "Structural motifs on apoA-I mimetic peptide for cholesterol efflux" International Atherosclerosis Society Meeting, Rome, Italy, June 2006
67. "Effect of apoA-I mimetic peptides on atherosclerosis in mice" International Atherosclerosis Society Satellite Meeting, Parma, Italy, June 2006
68. "From Tangier disease to super HDL: A 40 year journey" Pathology Grand Rounds, Johns Hopkins Medical School, Baltimore, MD, Dec. 2006
69. "HDL: Update from diagnostics to therapeutics" Joint AACC and Amer. Soc. Clin Lab Science meeting. Honolulu, HI, May 2006
70. "Tangier disease and HDL metabolism" Ohio State Univ. Feb. 2006
71. "Intraoperative testing of PTH and other endocrine hormones" Amer. Society of Clinical Pathology, Seattle, Sept. 2005
72. "Interaction of apolipoproteins with the ABCA1 transporter" 5th Annual HDL-Metabolic Pathway and Drug Target meeting, Boston, Ma., Mar. 2004
73. "ABCA1 transporters and reverse cholesterol transport" NIH-Demystifying Medicine Seminar, Bethesda, MD, Apr. 2003
74. "ABC transporters and cholesterol metabolism" Molecular Pathology Seminar series, Johns Hopkins Medical School, Baltimore, MD, Apr. 2003
75. "Multi-dimensional ROC plots for assessing misclassification costs" International Federation of Clinical Chemistry, Kyoto, Japan, Oct. 2002
76. "HDL and atherosclerosis" Lipoproteins and Vascular Disease Seminar, AACC meeting, Orlando, FL, July 2002
77. "The use of ROC curves in medical decision making" Biomedical Computing Interest Group, NIH, Bethesda, MD. June 2002

78. "ABC transporters and reverse cholesterol transport: New insights from Tangier disease" Univ. Pittsburgh Medical School. Sept. 2002
79. "ABC transporters and reverse cholesterol transport: New insights from Tangier disease" Keynote speaker 4th Annual Leonard Jarret Honorary research symposium. Univ. Pennsylvania Medical School. June. 2002
80. "Apolipoprotein substrate specificity of the ABCA1 transporter" South East Lipid Meeting, Atlanta, GA, Oct. 2001
81. "Interaction of apoA-I mimetic peptides with the ABCA1 transporter" Rockefeller Univ., March 2001.
82. "ABCA1 Transporter: Role in HDL mediated Cholesterol efflux and Tangier disease" NIH-Clinical Center Grand Rounds, Bethesda, MD, Apr. 2001
83. "Molecular Defects in the ABCA1 transporter leads to defective intracellular lipid trafficking in Tangier disease" NIH Research Festival symposium. Bethesda, MD. Oct. 2000
84. "Intraoperative immunoassay testing for endocrine tumors" NIH-Clinical Center Grand Rounds, Bethesda, MD, Oct. 1999
85. "Use of neural networks for quality control" Diagnostic Products Company seminar at Amer. Assoc Clinical Chemistry meeting, New Orleans, July 1998
86. "Rapid assays for the intraoperative measurement of hormones" Nichols Institute, San Juan Capistrano, CA, Sept. 1998
87. "Differential hepatic gene expression in cholesterol fed rabbits". Mass General Hospital, Dept. Pathology, Nov. 1994
88. "Identification of cholesterol regulated genes from PCR subtraction libraries." Dept. Pathology, Univ Alabama, Sept. 1994
89. "Differential hepatic gene expression in cholesterol fed rabbits". Baylor Univ, Dept. Pathology, Nov. 1994
90. "Identification of cholesterol regulated genes from PCR subtraction libraries." Univ. Chicago, Dept. Pathology, Dec. 1994

Publications:

Citation Indices (as of April 24, 2017)

Total citations: 10782
Mean citations per paper: 25.8
Citations in 2016: 1397
H-index: 53

Peer Reviewed

1. Bartman CD, Doerfler DL, Bird BA, **Remaley AT**, Peace JN, Campbell IM. Mycophenolic acid production by *Penicillium brevicompactum* on solid media. *Appl Env Microbiol.* 1981;41:729-36.
2. Bird BA, **Remaley AT**, Campbell IM: Brevianamides A and B are formed only after Conidiation has begun in Solid Cultures of *Penicillium brevicompactum*. *Appl. Env. Microbiol.* 1981;42:521-525.

3. Campbell, IM, Doerfler DL, Bird, BA, **Remaley AT**, Rosato LM, Davis BN. Secondary Metabolism and Colony Development in Solid cultures of *Penicillium brevicompactum* and *Penicillium patulum*. FEMS Symp. 1983;13:141-151.
4. **Remaley AT**, Kuhns DB, Basford RE, Glew RH, Kaplan S. Leishmanial Phosphatase Blocks Neutrophil Superoxide Anion Production. J. Biol. Chem., 259:11173-11175, 1984.
5. Saha, A.K.; Dowling, J.N.; LaMarco, K.L.; Das, S.; **Remaley, A.T.**; Olomu, N.; Pope, M.T.; Glew, R.H.: Properties of an Acid Phosphatase from *Legionella micdadei* which Blocks Superoxide Anion Production by Human Neutrophils. Arch. Biochem. Biophys., 243:150-160, 1985.
6. **Remaley, A.T.**; Das, S.; Campbell, P.I.; LaRocca, G.M.; Pope, M.T.; Glew, R.H.: Characterization of *Leishmania donovani* Acid Phosphatases. J. Biol. Chem., 260:880-886, 1985.
7. **Remaley, A.T.**; Glew, R.H.; Kuhns, D.B.; Basford, R.E.; Waggoner, A.S.; Ernst, L.A.; Pope, M.B.: *Leishmania donovani*: Surface Membrane Acid Phosphatase Blocks Neutrophil Oxidative Metabolite Production. Exp. Parasitol., 60:331-341, 1985.
8. Das, S.; Saha, A.K.; **Remaley, A.T.**; Glew, R.H.; Dowling, J.N.; Kajiyashi, M.; Gottlieb, M.: Hydrolysis of Phosphoproteins and Inositol Phosphates by Cell Surface Phosphatase of *Leishmania donovani*. Molec. and Biochem. Parasitol., 20:143-153, 1986.
9. **Remaley, A.T.**; Kennedy, J.M.; Laposata, M.: Evaluation of the Clinical Utility of Platelet Aggregation Studies. Amer. J. Hematol., 31:188-93, 1988
10. **Remaley, A.T.**; Hicks, D.G.; Kane, M.; Shaw, L.S.: Laboratory Assessment of Poisoning with a Carbamate Insecticide. Clin. Chem., 34:1933-1936, 1988
11. **Remaley, A.T.**; Bulley, M.; Senior, M.B.; Goodman, D.B.P.: Discordant hCG Measurements in a Patient with a Carcinoma. Clin. Chem., 35:1259-60, 1989
12. **Remaley, A.T.**; Goodman, D.B.P.: Markedly Increased Concentrations of Ferritin in an AIDS Patient with Disseminated Histoplasmosis. Clin. Chem., 36:1992-3, 1990
13. Burger, S.R.; **Remaley, A.T.**; Danley, J. M.; Moore J.S., Muchelle, R.J.; Wunner, W.H., Spitalnik, S.L.: Stable Expression of Rabies Virus Glycoprotein in Chinese Hamster Ovary Cells. J. Gen. Virol., 72:359-367, 1991
14. **Remaley, A.T.**; Ugorski, M.; Wu, N.; Burger, S.R.; Moore, J.S.; Fukuda, M.; Spitalnik, S.L.: Expression of Human Glycophorin A in Chinese Hamster Ovary Cells Defective in Glycosylation. J. Biol. Chem., 266:24176-24183, 1991
15. Shakin-Eshleman, S.H.; **Remaley, A.T.**; Eshleman, J.R.; Wunner, W.H.; Spitalnik, S.L.: N-Linked Glycosylation of Rabies Virus Glycoprotein: Individual Sequons Differ in their Glycosylation Efficiencies and Influence on Cell Surface Expression. J. Biol. Chem., 267: 10690-10698, 1992
16. **Remaley, A. T.**; Wong, A.W.; Schumacher, U.K.; Meng, M.S.; Brewer, H.B.; Hoeg, J.M.: O-Linked Glycosylation Modifies the Association of Apolipoprotein A-II to High Density Lipoproteins. J. Biol. Chem., 268: 6785-6790, 1993
17. Schmidt, H.J.; **Remaley, A.T.**; Stonik, J.A.; Ronan, R.; Wellmann, A.; Thomas, F.; Zech, L.A.; Brewer, H.B.; Hoeg, J.M.: Carboxy-terminal Domain Truncation Alters Apolipoprotein A-I in vivo Catabolism. J. Biol. Chem., 270: 5469-5478, 1995
18. **Remaley, A.T.**; Hoeg, J.M.: Polarized Secretion of Apolipoprotein A-I and Apolipoprotein A-II by MDCK Cells. J. Lipid Res., 36: 407-413, 1995
19. **Remaley, A.T.**; Schumacher, U.K.; Brewer, H.B.; Hoeg, J.M.: Identification of Novel Differentially Expressed Hepatic Genes in Cholesterol-fed Rabbits by a Non-targeted Gene Approach. J. Lipid Res., 36: 308-314, 1995

20. Berard, A.M.; Foger B.; **Remaley A.T.**; Shamburek R.; Vaisman B.V.; Talley G.D Paigen B.; Hoyt R.F.; Marcinoval S.; Brewer H.B.; Santamarina-Foho S: High Plasma HDL Concentrations Associated with Enhanced Atherosclerosis in Transgenic Mice Overexpressing Lecithin Cholesterol-Acyl Transferase. *Nature Medicine*, 3: 744-749, 1997
21. **Remaley A.T.**; Schumacher U.K.; Stonik J.A.; Nazih H.; Brewer H.B.: Decreased reverse cholesterol transport from Tangier disease fibroblasts: Acceptor specificity and effect of brefeldin on lipid efflux. *Arterioscler. Thromb. Vasc. Biol.* 17: 1813-21, 1997
22. Schmidt H.H-J.; Hass R.E.; **Remaley A**; Genschel J.; Strassburg C.P.; Buttner C.; and Manns M.P.: *In vivo* kinetics as a sensitive method for testing physiologically intact human recombinant apolipoprotein A-I: Comparison of three different expression systems. *Clin. Chim. Acta*, 268: 41-60, 1997
23. **Remaley A.T.**; Farsi B.D.; Hoeg J.M.; Brewer H.B.: Differential Rate of Cholesterol Efflux from the Apical and Basolateral Membranes of MDCK cells. *J. of Lipid Res*, 39: 1231-1238, 1998
24. Weil R.J.; Wu Y.-W.; Vortmeyer M.D.; Moon Y.-W.; Delgado R.M.; Fuller B.G.; Lonser R.R.; **Remaley A.T.**; Zhuang Z.: Telomerase Activity in Microdissected Human Gliomas. *Modern Pathology* 12:41-6, 1999
25. **Remaley A.T.**; Sampson M.L.; DeLeo J.M., Remaley N.A.; Farsi B.D.; Zweig M.H. Prevalence-value-accuracy plots: A new method for comparing tests based on the cost of misclassifications. *Clinical Chemistry* 45:934-41, 1999
26. Orban Z, **Remaley A.T.**, Sampson M., Trajanoski Z, Chrousos G.P. The differential effect of food intake and adrenergic stimulation on adipose derived hormones and cytokines in man. *Metabolism* 48:2126-33, 1999.
27. Hammad SM; Stefansson S; Twal WO; Drake CJ; Fleming P; **Remaley AT**; Brewer HB Jr; Argraves WS. Cubilin, the endocytic receptor for intrinsic factor-vitamin B(12) complex, mediates high-density lipoprotein holoparticle endocytosis. *Proc Natl Acad Sci U S A.* 96(18):10158-63, 1999
28. **Remaley AT**, M. Rosier, C. Knapper, K.M. Peterson, C. Koch, M. Dinger N. Duverger, G. Assman, M. Dean, S. Santamarina-Fojo, D.S. Fredrickson, P. Deneffe and H.B. Brewer Jr. Human ATP Binding Cassette Transporter 1 (ABCA1): Genomic Organization and Identification of the Genetic Defect in the Original Tangier Disease Kindred. *Proc Natl Acad Sci U S A.* 96(22):12685-90, 1999
29. Libutti S.K, Alexander, H.R., Bartlett, D.L., Sampson, M.L., Ruddel, M.E., Skarulis, M., Marx, S.J, Spiegel, A.M., Simmonds, W., **Remaley, A.T.**: Kinetic analysis of the rapid intraoperative PTH hormone assay in patients during operation for hyperparathyroidism. *Surgery* 126(6):1145-50, 1999
30. Simone, NL, **Remaley AT**, Charboneau L, Pettricino EF, Glickman JW, Emmert-Buck MR, Fleischer TA, Liotta LA. Sensitive immunoassay of tissue cell proteins procured by laser capture microdissection. *Amer. J. of Path.* 156(2):445-452, 2000
31. Bradley DW, Hess RA, Tao F, Sciaba-Lentz L, **Remaley AT**, Laugharn JA, Manak M. Pressure Cycling Technology: A novel approach to viral inactivation in plasma. *Transfusion* 40,193-200, 2000.
32. Wu, Y-Y, Hruszkewycz, A.M., Delgado, RM, Yang, A, Vortmeyer, O., Moon, Y-W, Weil, RJ, Zhuang, Z, and **Remaley AT**, Limitations of the quantitative determination of telomerase activity by the electrophoretic and ELISA based TRAP assays. *Clin. Chim. Acta* 293, 199-212, 2000.
33. Sampson ML, G. Csako, and **Remaley AT**, Estimation of Serum Apolipoprotein B by a Modified Homogeneous Assay for High-Density Lipoprotein-Cholesterol. *Clin. Chem.* 46, 869-871, 2000
34. Santamarina-Foho, S, Peterson K, Knapper C, **Remaley AT**, Freeman L, Xiao-Ping Y, Chimini G, Blackmon E, Francois T, Deneffe P, Duverger N, Fredrickson DS, Brewer HB. Complete genomic sequence of the human ABCA1 gene: Functional analysis of the ABCA1 promoter. *Proc Natl Acad Sci U S A.* 2000 Jul 5;97(14):7987-7992.

35. Sampson, ML, Csako G, **Remaley AT**. Dual HDL/Total cholesterol test: A single tube homogenous assay for the sequential measurement of HDL-cholesterol and total cholesterol. *Ann. of Clin. Biochem.* 2000 37 (Pt 4):479-87
36. Collins MT, **A.T. Remaley**, G. Csako, F. Pucino, M.C. Skarulis, J.E. Balow, and N.J. Sarlis. Increased Levothyroxine Requirements Presenting as 'Inappropriate' TSH Secretion Syndrome in a Patient with Nephrotic Syndrome. *J Endocrinol Invest.* 2000 23(6):383-92
37. Woods, JM, Sampson, ML, and **Remaley AT**. Rapid intraoperative cortisol assay: Design and utility for localizing adrenal tumors by venous sampling. *Clinical Biochemistry* 2000, 33(6):501-503.
38. Bocharov AV, Vishnyakova TG, Baranova IN, **Remaley AT**, Patterson AP, Eggerman TL. Heat shock protein 60 is a high affinity high density lipoprotein binding protein. *Biochem. Biophys Res. Commun.*, 2000, 277(1):228-35.
39. Shulenin S, Schriml LM, **Remaley AT**, Fojo S, Brewer HB, Allikmets R, and Dean M. A liver-specific ATP-binding cassette gene (*ABCG5*) from the ABCG (White) gene subfamily maps to human chromosome 2p21 in the region of the Sitosterolemia locus. *Cyto. Cell Genet.* 92:204-208, 2001
40. Sampson ML, Aubrey A, Csako G, **Remaley AT**. Triple lipid screening test: A homogenous assay for HDL-cholesterol, total cholesterol and triglycerides. *Clin. Chem.*, 2001, 47:532-9
41. Uwaifo GI, **Remaley AT**, Stene M, Reynolds JC, Yen PM, Snider RH, Becker KL, Sarlis NJ. A Case of Spurious Hypercalcitoninemia: A Cautionary Tale on the Use of Plasma Calcitonin Assays in the Screening of Patients with Thyroid Nodules for Neoplasia. *J. Endocrinol. Invest.* 24(5):361-9, 2001
42. **Remaley AT**, John A. Stonik, Steven J. Demosky, Edward B. Neufeld, Alexander V. Bocharov, Tatyana G. Vishnyakova, Thomas L. Eggerman, Amy P. Patterson, Nicholas J. Duverger, Silvia Santamarina-Fojo, and H. Bryan Brewer Jr. Apolipoprotein specificity for lipid efflux by the human ABCA1 transporter *Biochem. Biophys Res. Commun.*, 2001, 280:818-823
43. Chinetti G, Lestavel S, Bocher V, **Remaley AT**, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart J-C, Clavey V, Staels B. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. *Nature Medicine*, 2001, 7: 48-52
44. G Lambert, N Sakai, B Vaisman, E. Neufeld, B Marteyn, C Chan, B Paigen, E Lupia, A Thomas, Liliane J. Striker, J Blanchette-Mackie, G Csako, J Brady, R Costello, G Striker, **AT. Remaley**, HB Brewer, and S Santamarina-Fojo. Analysis of Glomerulosclerosis and Atherosclerosis in Lecithin Cholesterol Acyltransferase Deficient Mice. *J. Biol. Chem* 4;276(18):15090-8, 2001
45. E B Neufeld, **AT Remaley**, JA Stonik, SJ. Demosky. AM. Cooney, M Comly, N Dwyer, J Blanchette-Mackie, S Santamarina-Fojo, and HB Brewer. Cellular Localization and Trafficking of the Human ABCA1 Transporter. *J. Biol. Chem* 276(29):27584-90, 2001
46. Santamarina-Fojo S, **Remaley AT**, Neufeld EB, Brewer HB Jr. Regulation and intracellular trafficking of the ABCA1 transporter. *J Lipid Res. Sep*;42(9):1339-45, 2001
47. Vaisman BL, Lambert G, Amar M, Joyce C, Ito T, Shamburek RD, Cain WJ, Fruchart-Najib J, Neufeld ED, **Remaley AT**, Brewer HB Jr, Santamarina-Fojo S. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. *J Clin Invest.* Jul;108(2):303-9, 2001
48. Charles W. Joyce, Marcelo J.A. Amar, Gilles Lambert, Boris L. Vaisman, Beverly Paigen, Jamila Najib-Fruchart, John S. Parks, Robert F. Hoyt, Jr., Edward D. Neufeld, **Alan T. Remaley**, Donald S. Fredrickson, H. Bryan Brewer, Jr., Silvia Santamarina-Fojo. The ATP Binding Cassette Transporter A1 (ABCA1) Modulates the Development of Aortic Atherosclerosis in C57BL/6 and ApoE-knockout Mice. *Proc Natl Acad Sci U S A.* Jan 8;99(1):407-12, 2002
49. Volpato, JM Guralnik, LP Fried, **AT Remaley**, AR Cappola, LJ Launer. Serum Thyroxine Level and Cognitive Decline in Euthyroid Older Women. *Neurology* Apr 9;58(7):1055-61, 2002

50. Xu M, Chan Y, Fischer SH, **Remaley AT**. Improvement of AMPLICOR Human Immunodeficiency Virus Type 1 Viral Load Test (Version 1.5) by Addition of a Coprecipitant during the RNA Isolation Step J Clin Microbiol. 2002 Jul; 40(7):2616-7.
51. Yang XP, Freeman LA, Knapper CL, Amar MJ, **Remaley AT**, Brewer HB Jr, Santamarina-Fojo S. The E-box motif in the proximal ABCA1 promoter mediates transcriptional repression of the ABCA1 gene. J Lipid Res. 2002 Feb; 43(2):297-306, 2002.
52. Charmandari E, Calis KA, Keil MF, Mohassel MR, **Remaley A**, Merke DP. Flutamide decreases cortisol clearance in patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2002 Jul;87(7):3197-200
53. Baranova I, Vishnyakova T, Bocharov A, Chen Z, **Remaley AT**, Stonik J, Eggerman TL, Patterson AP. Lipopolysaccharide down regulates both scavenger receptor B1 and ATP binding cassette transporter A1 in RAW cells. Infect Immun. 2002 Jun;70(6):2995-3003
54. Kim IY, Seong do H, Kim BC, Lee DK, **Remaley AT**, Leach F, Morton RA, Kim SJ. Raloxifene, a Selective Estrogen Receptor Modulator, Induces Apoptosis in Androgen-responsive Human Prostate Cancer Cell Line LNCaP through an Androgen-independent Pathway. Cancer Res. 2002 Jul 1; 62(13):3649-53.
55. **Remaley AT**, Bark S, Walts AD, Freeman L, Shulenin S, Annilo T, Elgin E, Rhodes HE, Joyce C, Dean M, Santamarina-Fojo S, Brewer HB. Comparative genome analysis of potential regulatory elements in the ABCG5-ABCG8 gene cluster. Biochem Biophys Res Commun. 2002 295(2):276-82.
56. Elaraj D, **Remaley AT**, Simonds W, Skarulis M, Libutti S, Bartlett D, Venzon D, Marx S, Alexander HR. Utility of rapid intraoperative PTH assay to predict severe post-op hypocalcemia in patients after re-operation of hyperparathyroidism. Surgery. 2002 Dec;132(6):1028-33
57. Charles D. Bolan,, Stacey A. Cecco, Robert A. Wesley, McDonald Horne, Yu Ying Yau, **Remaley AT**, Richard W. Childs, A. John Barrett, Nadja N. Rehak, Susan F. Leitman. Controlled Study of Citrate Effects and Response to Intravenous Calcium Administration During Allogeneic Peripheral Blood Stem Cell Donation. Transfusion , 2002 Jul 42(7):935-46
58. Neufeld EB, Demosky SJ Jr, Stonik JA, Combs C, **Remaley AT**, Duverger N, Santamarina-Fojo S, Brewer HB Jr. The ABCA1 transporter functions on the basolateral surface of hepatocytes. Biochem Biophys Res Commun. 2002 Oct 4; 297(4):974-9.
59. Albright SV, McCart JA, Libutti SK, Bartlett DL, Alexander HR, Sampson ML, Ruddel ME, **Remaley AT**. Rapid measurement of insulin using Abbott IMx: Application to the management of insulinoma. 2002 Ann Clin Biochem. 2002 Sep; 39(Pt 5): 513-5.
60. Vishnyakova TG, Bocharov AV, Baranova IN, Chen Z, **Remaley AT**, Csako G, Eggerman TL, Patterson AP. Binding and internalization of lipopolysaccharide by Cla-1, a human orthologue of rodent scavenger receptor B1. J Biol Chem. Jun 2003;278(25):22771-80.
61. Basso F, Freeman L, Knapper CL, **Remaley AT**, Stonik J, Neufeld EB, Tansey T, Amar MJ, Fruchart-Najib J, Duverger N, Santamarina-Fojo S, Brewer HB Jr. Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations. J Lipid Res. 2003 Feb;44(2):296-302.
62. **Remaley AT**, Thomas F, Stonik JA, Demosky SJ, Bark SE, Neufeld EB, Bocharov AV, Vishnyakova TG, Patterson AP, Eggerman TL, Santamarina-Fojo S, Brewer HB. Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res. 2003 Apr;44 (4):828-36.
63. Xu M, Chan Y, Fischer SH, **Remaley AT**. Automated procedure for improving the RNA isolation step in viral load testing for human immunodeficiency virus. J Clin Microbiol. 2004 Jan;42(1):439-40.

64. Libutti SK, Crabtree JS, Lorang D, Burns AL, Mazzanti C, Hewitt SM, O'Connor S, Ward JM, Emmert-Buck MR, **Remaley AT**, Miller M, Turner E, Alexander HR, Arnold A, Marx SJ, Collins FS, Spiegel AM. Parathyroid gland-specific deletion of the mouse *Men1* gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism. *Cancer Res.* 2003 Nov 15;63(22):8022-8.
65. Neufeld EB, Stonik JA, Demosky SJ, Knapper CA, Combs CA, Cooney A, Comly M, Dwyer N, Blanchette-Mackie J, **Remaley AT**, Santamarina-Fojo S, Brewer HB Jr. The ABCA1 transporter modulates late endocytic trafficking: Insights from the correction of the genetic defect in Tangier disease. *J Biol Chem.* 2004 Apr 9;279(15):15571-8.
66. Arakawa R, Hayashi M, **Remaley AT**, Brewer BH, Yamauchi Y, Yokoyama S. Phosphorylation and stabilization of ATP binding cassette transporter A1 by synthetic amphiphilic helical peptides. *J Biol Chem.* 2004 Feb 20;279(8):6217-20.
67. Freeman LA, Kennedy A, Wu J, Bark S, **Remaley AT**, Santamarina-Fojo S, Brewer HB. The orphan nuclear receptor LXR-1 activates the ABCG5/ABCG8 intergenic promoter. *J. Lipid Res.* 2004; 45:1197-206.
68. Drake SK, Bowen RA, **Remaley AT**, Hortin GL. Potential interferences from blood collection tubes in mass spectrometric analyses of serum polypeptides. *Clin Chem.* 2004 Dec;50(12):2398-401.
69. Stonik JA, **Remaley AT**, Demosky SJ, Neufeld EB, Bocharov A, Brewer HB. Serum amyloid A promotes ABCA1-dependent and ABCA1-independent lipid efflux from cells. *Biochem Biophys Res Commun.* 2004 Sep 3;321(4):936-41.
70. Penzak SR, Shen JM, Alfaro RM, **Remaley AT**, Natarajan V, Falloon J. Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes. *Ther Drug Monit.* 2004 Jun;26(3):322-30.
71. Bocharov AV, Baranova IN, Vishnyakova TG, **Remaley AT**, Csako G, Thomas F, Patterson AP, Eggerman TL. Targeting of scavenger receptor class B type I by synthetic amphipathic alpha-helical-containing peptides blocks lipopolysaccharide (LPS) uptake and LPS-induced pro-inflammatory cytokine responses in THP-1 monocyte cells. *J Biol Chem.* 2004 Aug 20;279(34):36072-82.
72. Bowen RA, Chan Y, Cohen J, Rehak NN, Hortin GL, Csako G, **Remaley AT**. Effect of blood collection tubes on total triiodothyronine and other laboratory assays. *Clin Chem.* 2005 Feb;51(2):424-33.
73. Baranova IN, Vishnyakova TG, Bocharov AV, Kurlander R, Chen Z, Kimelman ML, **Remaley AT**, Csako G, Thomas F, Eggerman TL, Patterson AP. Serum Amyloid A Binding to CLA-1 (CD36 and LIMPII Analogous-1) Mediates Serum Amyloid A Protein-induced Activation of ERK1/2 and p38 Mitogen-activated Protein Kinases. *J Biol Chem.* 2005 Mar 4;280(9):8031-40.
74. Bowen RA, Chan Y, Ruddel ME, Hortin GL, Csako G, Demosky SJ Jr, **Remaley AT**. Immunoassay Interference by a Commonly Used Blood Collection Tube Additive, the Organosilicone Surfactant SL-720. *Clin Chem.* 2005;51:1874-82
75. Leach FS, Koh MS, Chan YW, Bark S, Ray R, Morton RA, **Remaley AT**. Prostate Specific Antigen as a Clinical Biomarker for Prostate Cancer. *Cancer Biol Ther.* 2005;4:371-5.
76. Irie F, Strozyk D, Peila R, Korf ES, **Remaley AT**, Masaki K, White LR, Launer LJ. Brain lesions on MRI and endogenous sex hormones in elderly men. *Neurobiol Aging.* 2006 Aug;27(8):1137-44.
77. Hortin GL, Shen RF, Martin BM, **Remaley AT**. Diverse range of small peptides associated with high-density lipoprotein. *Biochem Biophys Res Commun.* 2006;340:909-15.
78. Joyce CW, Wagner EM, Basso F, Amar MJ, Freeman LA, Shamburek RD, Knapper CL, Syed J, Wu J, Vaisman BL, Fruchart-Najib J, Billings EM, Paigen B, **Remaley AT**, Santamarina-Fojo S, Brewer HB Jr. ABCA1 overexpression in the liver of LDLr-KO mice leads to accumulation of Pro-atherogenic lipoproteins and enhanced atherosclerosis. *J Biol Chem.* 2006; 281:33053-65.

79. Khoromi S, Muniyappa R, Nackers L, Gray N, Baldwin H, Wong KA, Matheny LA, Moquin B, Rainer A, Hill S, **Remaley AT**, Johnson LL, Max MB, Blackman MR. Effects of Chronic Osteoarthritis Pain on Neuroendocrine Function in Men. *J Clin Endocrinol Metab*. 2006; 91:4313-8.
80. Yanoff LB, Parikh SJ, Spitalnik A, Denkinger B, Sebring NG, Slaughter P, McHugh T, **Remaley AT**, Yanovski JA. The prevalence of hypovitaminosis D and secondary hyperparathyroidism in obese Black Americans. *Clin Endocrinol*. 2006 May;64(5):523-9.
81. Nishiwaki M, Ikewaki K, Bader G, Nazih H, Hannuksela M, **Remaley AT**, Shamburek RD, Brewer HB Jr. Human lecithin:cholesterol acyltransferase deficiency: in vivo kinetics of low-density lipoprotein and lipoprotein-X. *Arterioscler Thromb Vasc Biol*. 2006 Jun;26(6):1370-5.
82. Nofer JR, **Remaley AT**, Feuerborn R, Wolinnska I, Engel T, von Eckardstein A, Assmann G. Apolipoprotein A-I activates Cdc42 signaling through the ABCA1 transporter. *J Lipid Res*. 2006 Apr;47(4):794-803.
83. Marshall DA, Vernalis MN, **Remaley AT**, Walizer EM, Scally JP, Taylor AJ. The role of exercise in modulating the impact of an ultralow-fat diet on serum lipids and apolipoproteins in patients with or at risk for coronary artery disease. *Am Heart J*. 2006 Feb;151(2):484-91.
84. Hassan R, **Remaley AT**, Sampson ML, Zhang J, Cox DD, Pingpank J, Alexander R, Willingham M, Pastan I, Onda M. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. *Clin Cancer Res*. 2006 Jan 15;12(2):447-53.
85. Vishnyakova TG, Kurlander R, Bocharov AV, Baranova IN, Chen Z, Abu-Asab MS, Tsokos M, Malide D, Basso F, **Remaley AT**, Csako G, Eggerman TL, Patterson AP. CLA-1 and its splicing variant CLA-2 mediate bacterial adhesion and cytosolic bacterial invasion in mammalian cells. *Proc Natl Acad Sci U S A*. 2006 Nov 7;103(45):16888-93.
86. Basso F, Amar MJ, Wagner EM, Vaisman B, Paigen B, Santamarina-Fojo S, **Remaley AT**. Enhanced ABCG1 expression increases atherosclerosis in LDLr-KO mice on a western diet. *Biochem Biophys Res Commun*. 2006 Dec 15;351(2):398-404.
87. Muller M, Klein I, Kopacsi S, **Remaley AT**, Rajnavolgyi E, Sarkadi B, Varadi A. Co-expression of human ABCG5 and ABCG8 in insect cells generates an androstan stimulated membrane ATPase activity. *FEBS Lett*. 2006 Nov 13;580(26):6139-44.
88. Hortin G, **Remaley AT**. Mass determination of major plasma proteins by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *Proteomics* 2006;2:103-115.
89. Lindsay JR, Shanmugam VK, Oldfield EH, Remaley AT, Nieman LK. A comparison of immunometric and radioimmunoassay measurement of ACTH for the differential diagnosis of Cushing's syndrome. *J. Endocrinol. Invest*. 2006;29:983-8.
90. Geerlings MI, Strozyk D, Masaki K, **Remaley AT**, Petrovitch H, Ross GW, White LR, Launer LJ. Endogenous sex hormones, cognitive decline, and future dementia in old men. *Ann Neurol*. 2007; 28:62-8.
91. Strozyk D, White LR, Petrovitch H, Geerlings MI, **Remaley AT**, Launer LJ. Sex hormones and neuropathology in elderly men: The HAAS. *Neurobiol Aging*. 2007 Jan;28(1):62-8.
92. Bowen RA, Vu C, **Remaley AT**, Hortin GL, Csako G. Differential effect of blood collection tubes on total free fatty acids (FFA) and total triiodothyronine (TT3) concentration: A model for studying interference from tube constituents. *Clin Chim Acta*. 2007 Mar;378(1-2):181-93.
93. Basso F, Freeman LA, Ko C, Joyce C, Amar MJ, Shamburek RD, Tansey T, Thomas F, Wu J, Paigen B, **Remaley AT**, Santamarina-Fojo S, Brewer HB Jr. Hepatic ABCG5/G8 overexpression reduces apoB-lipoproteins and atherosclerosis when cholesterol absorption is inhibited. *J Lipid Res*. 2007 Jan;48(1):114-26.

94. Yanoff LB, Menzie CM, Denkinger B, Sebring NG, McHugh T, **Remaley AT**, Yanovski JA. Inflammation and iron deficiency in the hypoferremia of obesity. *Int. J. Obes.* 2007 Sep;31(9):1412-9.
95. Prueitt RL, Boersma BJ, Howe TM, Goodman JE, Thomas DD, Ying L, Pfiester CM, Yfantis HG, Cottrell JR, Lee DH, **Remaley AT**, Hofseth LJ, Wink DA, Amb S. Inflammation and IGF-I activate the Akt pathway in breast cancer. *Int J Cancer.* 2007 Feb 15;120(4):796-805.
96. Williamson P, Halleck MS, Malowitz J, Ng S, Fan X, Krahling S, **Remaley AT**, Schlegel RA. Transbilayer phospholipids movements in ABCA1-deficient cells. *PLoS ONE.* 2007; 2:e729.
97. Chung E, **Remaley AT**, Launer LJ. Human serum albumin levels and cardiovascular risk factors in elderly Japanese-American men: The Honolulu Heart Program. *Hawaii Medical J.* 2007 Jun;66(6):148, 150-2.
98. Edison RJ, Berg K, **Remaley AT**, Kelley R, Rotimi C, Stevenson RE, Muenke M. Adverse birth outcome among mothers with low serum cholesterol. *Pediatrics.* 2007 Oct;120(4):723-33.
99. Mukhamedova N, Fu Y, Bukrinski M, **Remaley AT**, Sviridov D. The role of different regions of ATP-Binding Cassette Transporter A1 in cholesterol efflux. *Biochem.* 2007 Aug 21;46(33):9388-98.
100. Premkumar A, Venzon D, Avila N, Johnson D, **Remaley AT**, Forman M, Eng-Wong J, Zujewski JA, Stratton, P. Gynecologic and hormonal effects of raloxifene in pre-menopausal women. *Fertili Steril.* 2007 Dec;88(6):1637-44.
101. Flood A, Volker M, Pfeiffer R, Kahle L, **Remaley AT**, Clifford JR, Lanza E, Schatzkin A. The Effects of a High-Fruit and Vegetable, High-Fiber, Low-Fat Dietary Intervention on Serum Concentrations of Insulin, Glucose, IGF-I, and IGFBP-3. *Eur J of Clin Nutr.* 2008 Feb;62(2):186-96.
102. Flood A, Volker M, Pfeiffer R, Kahle L, **Remaley AT**, Schatzkin A. Elevated serum concentrations of insulin and glucose increase risk of recurrent colorectal adenomas. *Gastroenterology.* 2008 Apr;134(4):1268-9; author reply 1269-70.
103. De Jong FJ, Masaki K, Chen H, **Remaley AT**, Breteler MM, Peterovich H, White LR, Launer LJ. Thyroid function, the risk of dementia and neuropathologic changes: The Honolulu-Asia Aging Study. *Neurobiol Aging.* 2009 Apr;30(4):600-6.
104. Gomaschi M, Calabresi L, Rossoni G, Iametti S, Franceschini G, Stonik J, **Remaley AT**. Anti-inflammatory and cardioprotective activities of synthetic HDL containing apolipoprotein A-I mimetic peptides. *J Pharmacol Exp Ther.* 2008 Feb;324(2):776-83.
105. Wagner EM, Jean K-L, Artis JD, **Remaley AT**. Dietary alpha-cyclodextrin lowers low-density lipoprotein cholesterol and alters plasma fatty acid profile in low-density lipoprotein receptor knockout mice on a high fat diet. *Metabolism.* 2008 Aug;57(8):1046-51.
106. Horne M, **Remaley AT**. In vitro characterization of a monoclonal IgG-kappa from a patient with planar xanthomatosis. *Eur J Hematol.* 2008 Jun;80(6):495-502.
107. Sampson M, Rehak N, Sokoll L, Ruddle M, Gerhardt G, **Remaley AT**. Time adjusted sensitivity analysis: A systematic approach for optimizing delta check rules. *J Clin Ligand Assay.* 2008 (In Press).
108. Kwon GP, Schroeder JL, Amar MJ, **Remaley AT**, Balaban RS. Contribution of macromolecular structure to the retention of low-density lipoprotein at arterial branch points. *Circulation.* 2008 Jun 3;117(22):2919-27.
109. Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, **Remaley AT**, Schnohr P, Grande P, Tybjaerg-Hansen A. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. *JAMA.* 2008 Jun 4;299(21):2524-32.
110. Murphy AJ, Woollard KJ, Hoang A, Mukhamedova N, Stirzaker RA, McCormick Sp, **Remaley AT**, Sviridov D, Chin-Dusting J. High-Density Lipoprotein Reduces the Human Monocyte Inflammatory Response. *Arterioscler Thromb Vasc Biol.* 2008 Nov;28(11):2071-7.

111. Lindegaard ML, Wassif CA, Vaisman B, Amar M, Wasmuth EV, Shamburek R, Nielsen LB, **Remaley AT**, Porter FD. Characterization of placental cholesterol transport: ABCA1 is a potential target for in utero therapy of Smith-Opitz syndrome. *Hum Mol Genet.* 2008 Dec 1;17(23):3806-13.
112. Sethi AA, Stonik JA, Thomas F, Demosky SJ, Amar M, Neufeld E, Brewer HB, Davidson WS, D'Souza W, Sviridov D, **Remaley AT**. Asymmetry in the lipid affinity of bihelical amphipathic peptides: A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. *J Biol Chem.* 2008 Nov 21;283(47):32273-82.
113. Baranova IN, Kurlander R, Bocharov AV, Vishnyakova TG, Chen Z, **Remaley AT**, Csako G, Patterson AP, Eggerman TL. Role of human CD36 in bacterial recognition, phagocytosis, and pathogen-induced JNK-Mediated signaling. *J Immunol.* 2008 Nov 15;181(10):7147-56.
114. Yuditskaya S, Tumblin A, Hoehn GT, Wang G, Drake SK, Xu X, Ying S, Chi AH, **Remaley AT**, Shen RF, Munson PJ, Sufferdini AF, Kato GJ. Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell disease. *Blood.* 2009 Jan 29; 113(5):1122-8.
115. Wang J, Mansfield SG, Cota CA, Jiang PD, Wend K, Amar MJ, Brewer BH Jr, **Remaley AT**, McGarrity GJ, Garcia-Blanco MA, Puttaraju M. Trans-splicing into highly abundant albumin transcripts for production of therapeutic proteins in vivo. *Mol Ther.* 2009 Feb; 17(2):343-51.
116. Dowdell KC, Pesnicak L, Hoffmann V, Steadman K, **Remaley AT**, Cohen JL, Straus SE, Rao VK. Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas-deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS). *Exp Hematol.* 2009 Apr;37(4):487-94.
117. Amar MJ, Shamburek RD, Vaisman B, Knapper CL, Foger B, Hoyt RF Jr, Santamarina-Fojo S, Brewer BJ Jr, **Remaley AT**. Adenoviral expression of human lecithin-cholesterol acyltransferase in nonhuman primates leads to an antiatherogenic lipoprotein phenotype by increasing high-density lipoprotein and lowering low-density lipoprotein. *Metabolism.* 2009 Apr;58(4):568-75.
118. de Jong FJ, Masaki K, Chen H, **Remaley AT**, Breteler MM, Petrovitch H, White LR, Launer LJ. Thyroid function, the risk of dementia and neuropathologic changes: the Honolulu-Asia aging study. *Neurobiol Aging.* 2009 Apr;30(4):600-6.
119. Biesecker LG, Mullikin JC, Facio FM, Turner C, Cherukuri PF, Blakesley RW, Bouffard, GG, Chines PS, Cruz P, Hansen NF, Teer JK, Maskeri B, Young AC; NISC Comparative Sequencing Program, Manolini TA, Wilson AF, Finkel T, Hwang P, Arai A, **Remaley AT**, Sachdev V, Shamburek R, Cannon RO, Green ED. The ClinSeg Project: piloting large-scale genome sequencing for research in genomic medicine. *Gemone Res.* 2009 Sep;19(9):1665-74.
120. Hassan R, Schweizer C, Lu KF, Schuler B, **Remaley AT**, Weil SC, Pastan I. Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAB-009: Implications for cancer therapy. *Lung Cancer.* 2009 Sep 8. 68(3):455-9
121. Zeno SA, Deuster PA, Davis JL, Kim-Dorner SA, **Remaley AT**, Poth M. Cardiovascular fitness and risk factors of healthy African-Americans and Caucasians. *J Natl Med Assoc.* 2010 Jan; 102(1); 28-35.
122. Bowen RA, Hortin GL, Csako G, Otañez OH, **Remaley AT**. Impact of blood collection devices on clinical chemistry assays. *Clin Biochem.* 2010 Jan;43(1-2):4-25
123. Kim-Dorner SJ, Deuster PA, Zeno SA, **Remaley AT**, Poth M. Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance? *Metabolism.* 2010 Feb;59(2):299-304.
124. Tabet F, **Remaley AT**, Segaliny AI, Millet J, Yan L, Nakhla S, Barter PJ, Rye KA, Lambert G. The 5A Apolipoprotein A-I Memic Peptide Displays Anti-inflammatory and Antioxidant Properties in Vivo and In Vitro. *Arterioscler Thromb Vasc Biol.* 2010 Feb;30(2):246-52.

125. Bektas M, Allende ML, Lee BG, Chen W, Amar MJ, **Remaley AT**, Saba JD, Proia RL. Sphingosine 1-Phosphate lyase deficiency disrupts homeostasis in liver. *J. Biol. Chem.* 2010 April 2; 285 (14):10880-9.
126. Zeno SA, Deuster PA, Davis JL, Kim-Dorner SA, **Remaley AT**, Poth M. Diagnostic criteria for metabolic syndrome: Caucasians verses African-Americans. *Metab Syndr Relat Disord.* 2010 April; 8(2): 149-56.
127. Zorca S, Freeman L, Hildesheim M, Allen D, **Remaley AT**, Taylor AG 6th, Kato GJ. Lipid levels in sickle-cell disease associated with haemolytic severity , vascular dysfunction and pulmonary hypertension. *Br J Haematol.* 2010 May; 149 (3): 436-45.
128. Tumblin A, Tailor A, Hoehn GT, Mack AK, Mendelsohn L, Freeman L, Xu X, **Remaley AT**, Munson PJ, Suffredini AF, Kato GJ. Apolipoprotein A-I and serum amyloid A plasma levels are biomarkers of acute painful episodes in patients with sickle cell disease. *Haematologica.* 2010 Sep;95(9):1467-72.
129. Miller WG, Myers GL, Sakurabayashi I, Bachmann LM, Caudill SP, Dziekonski A, Edwards S, Kimberly MM, Korzun WJ, Leary ET, Nakajima K, Nakamura M, Nilsson G, Shamburek RD, Vetrovec GW, Warnick GR, **Remaley AT**. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. *Clin Chem.* 2010 Jun;56(6):977-86.
130. D'Souza W, Stonik JA, Murphy A, Demosky SJ, Sethi AA, Moore XL, Chin-Dusting J, **Remaley AT (co-senior author)**, Sviridov D. Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein. *Circ Res.* 2010 Jul 23;107(2):217-27.
131. Sethi AA, Sampson M, Warnick R, Muniz N, Vaisman B, Nordestgaard BG, Tybjaerg-Hansen A, **Remaley AT**. High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. *Clin Chem.* 2010 Jul;56(7):1128-37.
132. Draper DW, Madenspacher JH, Dixon D, King DH, **Remaley AT**, Fessler MB. ATP-binding cassette transporter G1 deficiency dysregulates host defense in the lung. *Am J Respir Crit Care Med.* 2010 Aug 1;182(3):404-12.
133. Morrow MP, Grant A, Mujawar Z, Dubrovsky L, Pushkarsky T, Kiselyeva Y, Jennelle L, Mukhamedova N, **Remaley AT**, Kashanchi F, Sviridov D, Bukrinsky M. Stimulation of the liver X receptor pathway inhibits HIV-1 replication via induction of ATP-binding cassette transporter A1. *Mol Pharmacol.* 2010 Aug;78(2):215-25.
134. Amar MJ, D'Souza W, Turner S, Demosky S, Sviridov D, Stonik J, Luchoomun J, Voogt J, Hellerstein M, Sviridov D, **Remaley AT**. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. *J Pharmacol Exp Ther.* 2010 Aug;334(2):634-41.
135. Sekine Y, Demosky SJ, Stonik JA, Furuya Y, Koike H, Suzuki K, **Remaley AT**. High-density lipoprotein induces proliferation and migration of human prostate androgen-independent cancer cells by an ABCA1-dependent mechanism. *Mol Cancer Res.* 2010 Sep;8(9):1284-94.
136. Rousset X, Vaisman B, Auerbach B, Krause BR, Homan R, Stonik J, Csako G, Shamburek R, **Remaley AT**. Effect of recombinant human lecithin cholesterol acyltransferase infusion on lipoprotein metabolism in mice. *J Pharmacol Exp Ther.* 2010 Oct;335(1):140-8.
137. Vickers KC, Palmisano BT, **Remaley AT**. The role of noncoding "junk DNA" in cardiovascular disease. *Clin Chem.* 2010 Oct;56(10):1518-20.
138. Yao X, Fredriksson K, Yu ZX, Xu X, Raghavachari N, Keeran KJ, Zywicke GJ, Kwak M, Amar MJ, **Remaley AT**, Levine SJ. Apolipoprotein E negatively regulates house dust mite-induced asthma via a low-density lipoprotein receptor-mediated pathway. *Am J Respir Crit Care Med.* 2010 Nov 15;182(10):1228-38.
139. Olivo-Marston SE, Mechanic LE, Mollerup S, Bowman ED, **Remaley AT**, Forman MR, Skaug V, Zheng YL, Haugen A, Harris CC. Serum estrogen and tumor-positive estrogen receptor-alpha are strong

- prognostic classifiers of non-small-cell lung cancer survival in both men and women. *Carcinogenesis*. 2010 Oct; 31(10):1778-86.
140. Celi FS, Brychta RJ, Linderman JD, Butler PW, Alberobello AT, Smith S, Courville AB, Lai EW, Costello R, Skarulis MC, Csako G, **Remaley AT**, Pacak K, Chen KY. Minimal changes in environmental temperature result in a significant increase in energy expenditure and changes in the hormonal homeostasis in healthy adults. *Eur J Endocrinol*. 2010 Dec; 163(6):863-72.
 141. Sarkar P, Luchowski R, Raut S, Sabnis N, **Remaley AT**, Lacko AG, Thamake S, Gryczynski Z, Gryczynski I. Studies on solvatochromic properties of aminophenylstyryl-quinolinium dye, LDS 798, and its application in studying submicron lipid based structure. *Biophys Chem*. 2010 Dec; 153(1):61-9.
 142. van Deventer HE, Mendu DR, **Remaley AT**, Soldin SJ. Inverse log-linear relationship between thyroid-stimulating hormone and free thyroxine measured by direct analog immunoassay and tandem mass spectrometry. *Clin Chem*. 2011 Jan;57(1):122-7.
 143. Yao X, Dai C, Fredriksson K, Dagur PK, McCoy JP, Qu X, Yu ZX, Keeran KJ, Zywicke GJ, Amar MJ, **Remaley AT**, Levine SJ. 5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust mite-induced asthma. *J Immunol*. 2011 Jan 1;186(1):576-83.
 144. van Deventer HE, Miller WG, Myers GL, Sakurabayashi I, Bachmann LM, Caudill SP, Dziekonski A, Edwards S, Kimberly MM, Korzun WJ, Leary ET, Nakajima K, Nakamura M, Shamburek RD, Vetovec GW, Warnick GR, **Remaley AT**. Non-HDL cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated LDL cholesterol in a dyslipidemic population. *Clin Chem*. 2011 Mar;57(3):490-501.
 145. Rosenson RS, Brewer HB Jr, Chapman MJ, Fazio S, Hussain MM, Kontush A, Krauss RM, Otvos JD, **Remaley AT**, Schaefer EJ. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. *Clin Chem*. 2011 Mar;57(3):392-410.
 146. Sekine Y, Osei-Hwedieh D, Matsuda K, Raghavachari N, Liu D, Furuya Y, Koike H, Suzuki K, **Remaley AT**. High fat diet reduces the expression of glutathione peroxidase 3 in mouse prostate. *2011*;71:1499.
 147. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, **Remaley AT**. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. *Nat Cell Biol*. 2011 Apr;13(4):423-33.
 148. Argraves KM, Sethi AA, Gazzolo PJ, Wilkerson BA, **Remaley AT**, Tybjaerg-Hansen A, Nordestgaard BG, Yeatts SD, Nicholas KS, Barth JL, Argraves WS. S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. *Lipids Health Dis*. 2011 May 9;10:70.
 149. Sekine Y, Suzuki K, **Remaley AT**. HDL and sphingosine-1-phosphate activate stat3 in prostate cancer DU145 cells via ERK1/2 and S1P receptors, and promote cell migration and invasion. *Prostate*. 2011 May 15;71(7):690-9.
 150. Li X, Johnson KR, Bryant M, Elkahloun AG, Amar M, Remaley AT, De Silva R, Halleneck JM, Quandt JA. Intranasal delivery of E-selectin reduces atherosclerosis in apoE^{-/-} mice. *PLoS One*. 2011;6: e20620
 151. Minniti CP, Wilson J, Mendelsohn L, Rigdon GC, Stocker JW, **Remaley AT**, Kato GJ. Anti-haemolytic effect of senicapoc and decrease in NT-proBNP in adults with sickle cell anaemia. *Br J Haematol*. 2011; 155: 634-6.
 152. Machado RF, Hildesheim M, Mendelsohn L, **Remaley AT**, Kato GJ, Gladwin MT. NT-pro brain natriuretic peptide levels and the risk of death in the cooperative study of sickle cell disease. *Br J Haematol*. 2011 Aug;154(4):512-20.
 153. Kang JG, Amar MJ, **Remaley AT**, Kwon J, Blackshear PJ, Wang PY, Hwang PM. Zinc finger protein tristetrprolin interacts with CCL3 mRNA and regulates tissue inflammation. *J Immunol*. 2011 Sep 1;187(5):2696-701.

154. Deuster, PA, Kim-Dorner SJ, **Remaley AT**, Poth M. Allosatic Load and Health Status of African Americans and Whites Am J Health Behav. 2011;35(6):641-53.
155. Kim KY, Stevens MV, Akter MH, Rusk SE, Huang RJ, Cohen A, Noguchi A, Springer D, Bocharov AV, Eggerman TL, Suen DF, Youle RJ, Amar M, **Remaley AT**, **Sack MN**. Parkin is a lipid-responsive regulator of fat uptake in mice and mutant human cells. J Clin Invest. 2011 Sep 1;121(9):3701-12.
156. Sviridov DO, Ikpot IZ, Stonik J, Drake SK, Amar M, Osei-Hwedieh DO, Piszczek G, Turner S, **Remaley AT**. Helix stabilization of amphipathic peptides by hydrocarbon stapling increases cholesterol efflux by the ABCA1 transporter. Biochem Biophys Res Commun. 2011;410:446-51.
157. Aicher BO, Haser E, Freeman L, Carnie A, Stonik J, Wang X, **Remaley AT**, Kato GJ, Cannon RO. Diet-induced Weight Loss in Overweight or Obese Women and Changes in High-density Lipoprotein Levels and Function. Obesity 2012;20:257.
158. Leelahavanichkul A, Bocharov AV, Kurlander R, Baranova IN, Vishnyakova TG, Souza AC, Hu X, Doi K, Vaisman B, Amar M, Sviridov D, Chen Z, **Remaley AT**, Csako G, Patterson AP, Yuen PS, Star RA, Eggerman TL. Class B Scavenger receptor types I and II and CD36 targeting improves sepsis survival and acute outcomes in mice. J Immunol 2012;188:2749-58.
159. Bowen RA, Dowdell KC, Dale JK, Drake SK, Fleisher TA, Hortin GL, **Remaley AT**, Nexo E, Rao VK. Elevated vitamin B12 levels in autoimmune lymphoproliferative syndrome attributable to elevated haptocorin in lymphocytes. Clin Biochem. 2012;45:490.
160. Vazquez E, Sethi AA, Freeman L, Zalos G, Chaudhry H, Haser E, Aicher BO, Aponte A, Gucek M, Kato GJ, Waclawiw, MA, **Remaley AT**, Cannon RO. High-density lipoprotein cholesterol efflux, nitration of apoA-I and endothelial function in obese women. Am J Cardiol. 2012;109:527-32.
161. Soleimanpour SA, Hirshberg B, Bunnell DJ, Sumner AE, Ader M, **Remaley AT**, Rother KI, Rickels MR, Harlan DM. Metabolic function of a suboptimal transplanted islet mass in non-human primates on rapamycin monotherapy. Cell Transplant. 2012;21:1297.
162. Yao X, Dai C, Fredriksson K, Lam J, Gao M, Keeran KJ, Nugent GZ, Qu X, Yu ZX, Jeffries N, Lin J, Kaler M, Shamburek R, Costello R, Csako G, Dahl M, Nordestgaard BG, **Remaley AT**, Levine SJ. Human apolipoprotein E genotypes differentially modify house dust mite-induced airway disease in mice. Am J Physiol Lung Cell Mol Physiol. 2012;301:206-15.
163. Vaisman BL, Demosky SJ, Stonik JA, Ghias M, Knapper CL, Samposn ML, Dai C, Levine SJ, **Remaley AT**. Endothelial expression of human ABCA1 in mice increases plasma HDL cholesterol and reduces diet-induced atherosclerosis. J Lipid Res. 2012;53:158-67.
164. Sable CA, Aliyu ZY, Dham NN, Nouraie M, Sachdev V, Sidenko S, Miasnikova GY, Polyakova LA, Sergueeva AI, Okhotin DJ, Bushuev V, **Remaley AT**, Niu X, Castro OI, Gladwin MT, Kato GJ, PrchalJT, Gordeuk VR. Pulmonary artery pressure and iron deficiency in patients with upregulation of hypoxia sensing due to homozygous VHL(R200W) mutation. Haematologica. 2012;97:193-200.
165. Davidson MH, Ballantyne CM, Jacobson TA, Bittner VA, Braun LT, Brown AS, Brown WV, Cromwell WC, Goldberg RB, McKenney JM, **Remaley AT**, Sniderman A, Toth PP, Tsimikas S, Ziajka PE, Maki KC, Dicklin MR. Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel on lipid specialists. J Clin Lipidol. 2011;5: 338-67.
166. Yavuz S, Simonds WF, Weinstein LS, Collins MT, Kebebew E, Nilubol N, Phan GQ, Libutti SK, **Remaley AT**, Van Deventer M, Marx SJ. Sleeping parathyroid tumor: Suppression of PTH secretion can hide overfunction. J Clin Endocrinol. Metab. 2012;97:1834-41.
167. Hoang A, Drew BG, Low H, **Remaley AT**, Nestel P, Kingwell BA, Sviridov D. Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein. Eur Heart J. 2012; 33(5):657-65.

168. Rogers MA, Liu J, Kushnir MM, Bryleva E, Rockwood AL, Meikle AW, Shapiro D, Vaisman BL, **Remaley AT**, Chang CC, Chang TY. Cellular pregnenolone sterification by acyl-CoA: cholesterol acyltransferase. *J Biol Chem.* 2012 May 18; 287 (21): 17483-92.
169. Draper DW, Gowdy KM, Madenspacher JH, Wilson RH, Whitehead GS, Nakano H, Pandiri AR, Foley JF, **Remaley AT**, Cook DN, Fessler MB. ATP binding cassette transporter G1 deletion induces IL-17-dependent dysregulation of pulmonary adaptive immunity. *J Immunol.* 2012 Jun 1; 188 (11): 5327-36.
170. Gold PW, Pavlatou MG, Carlson PJ, Luckenbaugh DA, Costello R, Bonne O, Csako G, Drevets WC, **Remaley AT**, Charney DS, Neumeister A, Kling MA. Unmedicated, remitted patients with major depression have decreased serum immunoglobulin A. *Neurosci Lett.* 2012;21:960-7.
171. Vickers KC, Shoucri BM, Levin MG, Wu H, Pearson DS, Osei-Hwedieh D, Collins FS, **Remaley AT (co-senior author)**, Sethupathy P. MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia. *Hepatology.* 2013;23:533-42.
172. Dai C, Yao X, Keeran KJ, Zywicke GJ, Qu X, Yu ZX, Dagur PK, McCoy JP, **Remaley AT**, Levine SJ. Apolipoprotein A-I attenuates ovalbumin-induced neutrophilic airway inflammation via a granulocyte colony-stimulating factor-dependent mechanism. *Am J Respir Cell Mol Biol.* 2012 Aug; 47 (2): 186-95.
173. Xu M, Liu K, Southall N, Marugan JJ, **Remaley AT**, Zheng W. A high-throughput sphingomyelinase assay using natural substrate. *Anal Bioanal Chem.* 2012 Aug; 404 (2): 407-14.
174. Vaisman BL, Andrews KL, Khong SM, Wood KC, Moore XL, Fu Y, Kepka-Lenhart DM, Morris SM Jr, **Remaley AT (co-senior author)**, Chin-Dusting JP. Selective endothelial overexpression of arginase II induces endothelial dysfunction and hypertension and enhances atherosclerosis in mice. *PLoS One.* 2012; 7 (7): e39487.
175. Yuan ZX, Rapoport SI, Soldin SJ, **Remaley AT**, Taha AY, Kellom M, Gu J, Sampson M, Ramsden CE. Identification and profiling of targeted oxidized linoleic acid metabolites in rat plasma by quadrupole time-of-flight mass spectrometry. *Biomed Chromatogr.* 2012;27:422.
176. Eisenhofer G, Lattke P, Herberg M, Siegert G, Qin N, Darr R, Hoyer J, Villringer A, Prejbisz A, Januszewicz A, **Remaley AT**, Martucci V, Pacak K, Ross HA, Sweep FC, Lenders JW. Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of pheochromocytoma. *Ann Clin Biochem.* 2012;50:62.
177. Lopera-Mesa TM, Mita-Mendoza NK, van de Hoef DL, Doumbia S, Konaté D, Doumbouya M, Gu W, Traoré K, Diakité SA, **Remaley AT**, Anderson JM, Rodriguez A, Fay MP, Long CA, Diakité, Fairhurst RM. *PLoS One.* 2012; 7 (10): e46424.
178. Mondul AM, Weinstein SJ, Bosworth T, **Remaley AT**, Virtamo J, Albanes D. Circulating thyroxine, thyroid-stimulating hormone, and hypothyroid status and the risk of prostate cancer. *PLoS One.* 2012; 7(10): e47730.
179. Madenspacher JH, Azzam KM, Gong W, Gowdy KM, Vitek MP, Laskowitz DT, Remaley AT, Wang JM, Fessler MB. Apolipoproteins and apolipoprotein mimetic peptides modulate phagocyte trafficking through chemotactic activity. *J Biol Chem.* 2012;287:4370.
180. Xu M, Liu K, Swaroop M, Porter FD, Sidhu R, Finkes S, Ory DS, Marugan JJ, Xiao J, Southall N, Pavan WJ, Davidson C, Walkley SU, **Remaley AT**, Baxa U, Sun W, McKew JC, Austin CP, Zheng W. δ -Tocopherol Reduces Lipid Accumulation in Niemann-Pick Type C1 and Wolman Cholesterol Storage Disorders. *J Biol Chem.* 2012 Nov 16; 287 (47): 39349-60.
181. Kotani K, Sakane N, Ueda M, Mashiba S, Hayase Y, Tsuzaki K, Yamada T, **Remaley AT**. Oxidized high-density lipoprotein is associated with increased plasma glucose in non-diabetic dyslipidemic subjects. *Clin Chim Acta.* 2012 Dec 24; 414: 125-9.

182. Del Valle-Pinero AY, Van Deventer HE, Fourie NH, Martino AC, Patel NS, **Remaley AT**, Henerson WA. Gastrointestinal permeability in patients with irritable bowel syndrome assessed using a four probe permeability solution. *Clin Chim Acta* 2013;418:97.
183. Chen K, Brychta R, Linderman J, Smith S, Courville A, Bill D, Herscovitch P, Millo CM, **Remaley AT**, Lee PC, Celli F. Brown fat activation mediates cold-induced thermogenesis in adult humans in response to a mild decrease in ambient temperature. *J Clin Endocrinol*:98:e1218.
184. Cole TG, Contois JH, Csako G, McConnel JP, **Remaley AT**, Deveraj S, Hoefner DM, Mallory T, Sethi AA, Warnick GR. Association of apoB and NMR LDL-P with outcomes in 25 clinical studies. *Clin Chem* 2013;59:1275.
185. Pavlatou MG, Vickers KC, Varma S, Malek R, Sampson M, **Remaley AT**, Gold PW, Skarulis MC, Kino T. Circulating cortisol-associated signature of glucocorticoid-related gene expression in subcutaneous fat of obese subjects. *Obesity* 2013;21:960.
186. Leon B, Jenkins S, Pepin K, Chaudhry H, Smith K, Zalos G, Miller BV, Chen KY, **Remaley AT**, Waclawiw MA, Sumner AE, Cannon RO. Insulin and extremity muscle mass in overweight and obese women. *Int. Jour. Obesity* 2013;37:1560.
187. Sviridov DO, Andrianov AM, Anischenko IV, Stonik JA, Amar MJ, Turner S, **Remaley AT**. Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting cholesterol efflux by the ABCA1 transporter. *J Pharmacol Exp Ther.* 2013; 344:50-58.
188. Ditiatkovski, M, D'Souza W, Kesani R, Chin-Dusting J, de Haan J, **Remaley AT**, Sviridov D. An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice. *PLoS One* 2013;8:e68802.
189. Oliveira MJ, van Deventer HE, Bachmann LM, Warnick GR, Nakajima K, Nakamura M, Sakurabayahi I, Kimberly MM, Shamburek RD, Korzun WJ, Myers GL, Miller WG, Miller RG, **Remaley AT**. Evaluation of four different equations for calculating LDL-C with eight different direct HDL-C assays. *Clin Chim Acta* 2013;423:135.
190. Tsai MY, Steffen BT, Guan W, McClelland RL, Warnick R, McConnell J, Hoefner DM, **Remaley AT**. New automated assay of small dense Low-Density Lipoprotein cholesterol identifies risk of coronary heart disease: The Multi-Ethnic Study of Atherosclerosis. *Atheroscler Thromb Vasc Biol* 2013;34:196.
191. Scoffone HM, Krajewski M, Zorca S, Bereal-Williams C, Little P, Seamon C, Mendelsohn L, Footman E, ABi-Jaoudeh N, Machado RF, Cuttica M, Shamburek R, Cannon RO, **Remaley AT**, Minniti CP, Kato GJ. Effect of extended-release niacin on serum lipids and on endothelial function in adults with sickle cell anemia and low high-density lipoprotein cholesterol levels. *Am J Cardiol* 2013;112:1499-504.
192. Vaisman BL, **Remaley AT**. Measurement of lecithin-cholesterol acyltransferase activity with the use of a peptide-proteoliposome substrate. *Methods Mol Biol.* 2013;1027:343-52.
193. Agnihothri RV, Courville AB, Linderman JD, Smith SM, Brychta RY, **Remaley AT**, Chen KY, Simchowitz, Celi F. Moderate weight loss is sufficient to affect thyroid hormone homeostasis and inhibits its peripheral conversion. *Thyroid* 2013;24:19
194. Jones RJ, Gu D, Bjorklund CC, Kuitse I, **Remaley AT**, Bashir T, Vreys V, Orłowski RZ. The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1. *J Pharmacol Exp Ther.* 2013;346:381-92.
195. Yang XP, Amar MJ, Vaisman B, Bocharov AV, Vishnyakova TG, Freeman LA, Kurlander RJ, Patterson AP, Becker LC, **Remaley AT**. Scavenger receptor-BI is a receptor for lipoprotein(a). *J Lipid Res.* 2013;54:2450-7.
196. Bowen RA, Sattayapiwat A, Gounden V, **Remaley AT**. Blood collection tube-related alternations in analyte concentrations in quality control material and serum specimens. *Clin Biochem* 2014;47:150

197. Simon-Manso Y, Lowenthal MS, Kilpatrick LE, Sampson ML, Telu KH, Rudnick PA, Mallard WG, Bearden DW, Schock TB, Tchekhovskoi DV, Blonder N, Yan X, Liang Y, Zheng Y, Wallace WE, Neta P, Phinney KW, **Remaley AT**, Stein SE. Metabolite profiling of a NIST Standard Reference material for human plasma: GC-MS, LC-MS, and clinical laboratory analysis, libraries and web-based resources. *Anal Chem* 2014;85:11725.
198. Asem O, Smith BT, Cooley MA, Wilkerson BA, Argraves KM, **Remaley AT**, Argraves WS. Cubulin maintains blood levels of HDL and albumin. *J Am Soc Nephrol* 2014;25:1028.
199. Tabet F, Vickers KC, Cuesta-Torres LF, Wiese CB, Shoucri BM, Lambert G, Catherinet C, Prado-Lourenco L, Levin MG, Thacker S, Sethupathy P, Barter PJ, **Remaley AT**, Rye K. HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. *Nature Comm.* 2014;5:3292.
200. Neufeld EB, O'Brien K, Walts AD, Stonik JA, Malide D, Combs CA, **Remaley AT**. The human ABCG1 transporter mobilized plasma membrane and late endosomal non-sphingomyelin-associated-cholesterol for efflux and esterification. *Biology (Basel)*. 2014 Dec 4;3(4):866-91
201. Meissner EG, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D, McHutchison J, Subramanian M, Sampson M, Naggie S, Patel K, **Remaley AT**, Masur H, Kottlil S. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. *Hepatology*. 2015; 61:790-801.
202. Pandey D, Bhunia A, Oh YJ, Chang F, Bergman Y, Kim JH, Serbo J, Boronina TN, Cole RN, Van Eyk J, **Remaley AT**, Berkowitz DE, Romer LH. OxLDL triggers retrograde translocation of arginase2 in aortic endothelial cells via ROCK and mitochondrial processing peptidase. *Circ Res*. 2014 Aug 1;115(4):450-9.
203. Dai C, Yao X, Vaisman B, Brenner T, Meyer KS, Gao M, Keeran KJ, Nugent GZ, Qu X, Yu ZX, Dagur PK, McCoy JP, **Remaley AT**, Levine SJ. ATP-binding cassette transporter 1 attenuates ovalbumin-induced neutrophilic airway inflammation. *Am J Respir Cell Mol Biol*. 2014 Nov;51(5):626-36.
204. Liu Z, Thacker SG, Fernandez-Castillejo S, Neufeld EB, **Remaley AT**, Bittman R. Synthesis of cholesterol analogues bearing BODIPY fluorophores by Suzuki or Liebeskind-Srogl cross-coupling and evaluation of their potential for visualization of cholesterol pools. *Chembiochem*. 2014 Sep 22;15(14):2087-96.
205. Stukas S, Freeman L, Lee M, Wilkinson A, Ossoli A, Vaisman B, Demosky S, Chan J, Hirsch-Reinshagen V, **Remaley AT**, Wellington CL. LCAT deficiency does not impair amyloid metabolism in APP/PS1 mice. *J Lipid Res*. 2014 Jun 20;55(8):1721-1729.
206. Jialal I, **Remaley AT**. Measurement of low-density lipoprotein cholesterol in assessment and management of cardiovascular disease risk. *Clin Pharmacol Ther*. 2014 Jul;96(1):20-2.
207. Vickers KC, Landstreet SR, Levin MG, Shoucri BM, Toth CL, Taylor RC, Palmisano BT, Tabet F, Cui HL, Rye KA, Sethupathy P, **Remaley AT**. MicroRNA-223 coordinates cholesterol homeostasis. *Proc Natl Acad Sci U S A*. 2014 Oct 7;111(40):14518-23.
208. Sibley CT, Estwick T, Zavodni A, Huang CY, Kwan AC, Soule BP, Long Priel DA, **Remaley AT**, Rudman Spergel AK, Turkbey EB, Kuhns DB, Holland SM, Malech HL, Zarembek KA, Bluemke DA, Gallin JI. Assessment of atherosclerosis in chronic granulomatous disease. *Circulation*. 2014 Dec 2;130(23):2031-9.
209. Amar MJ, Sakurai T, Sakurai-Ikuta A, Sviridov D, Freeman L, Ahsan L, **Remaley AT**. A novel apoC-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apoE-knockout mice. *J Pharmacol Exp Ther*. 2015 Feb;352(2):227-35.
210. Neufeld EB, O'Brien K, Walts AD, Stonik JA, Demosky SJ, Malide D, Combs CA, **Remaley AT**. Cellular localization and trafficking of the human ABCG1 transporter. *Biology (Basel)*. 2014 Nov 14;3(4):781-800.

211. Steffen BT, Guan W, **Remaley AT**, Paramsothy P, Heckbert SR, McClelland RL, Greenland P, Michos ED, Tsai MY. Use of lipoprotein particle measures for assessing coronary heart disease risk post-AHH/ACC guidelines: The multi-ethnic study of atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2015 Feb;35(2):448-54.
212. Hernáez Á, Fernández-Castillejo S, Farràs M, Catalán Ú, Subirana I, Montes R, Solà R, Muñoz-Aguayo D, Gelabert-Gorgues A, Díaz-Gil Ó, Nyyssönen K, Zunft HJ, de la Torre R, Martín-Peláez S, Pedret A, **Remaley AT**, Covas MI, Fitó M. Olive oil polyphenols enhance high-density lipoprotein function in humans: A randomized controlled trial. *Arterioscler Thromb Vasc Biol.* 2014 Sep;34(9):2115-9.
213. Jee YH, Celi FS, Sampson M, Sacks DB, **Remaley AT**, Kebebew E, Baron J. Midkine concentrations in fine-needle aspiration of benign and malignant thyroid nodules. *Clin Endocrinol (Oxf).* 2015 83(6):977-84.
214. Guo L, Zheng Z, Ai J, Howatt DA, Mittelstadt PR, Thacker S, Daugherty A, Ashwell JD, **Remaley AT**, Li XA. Scavenger receptor BI and high-density lipoprotein regulate thymocyte apoptosis in sepsis. *Arterioscler Thromb Vasc Biol.* 2014 May;34(5):966-75.
215. **Remaley AT**. HDL Cholesterol/HDL particle ratio: A new measure of HDL function? *J Am Coll Cardiol.* 2015 Feb 3;65(4):364-6.
216. Barochia AV, Kaler M, Cuento RA, Gordon EM, Weir NA, Sampson M, Fontana JR, MacDonald S, Moss J, Manganiello V, **Remaley AT**, Levine SJ. Serum ApoA-I and large HDL particles are positively correlated with FEV1 in atopic asthma. *Am J Respir Crit Care Med.* 2015; 91:990-1000.
217. Moraitis AG, Freeman LA, Shamburek RD, Wesley R, Wilson W, Grant CM, Price S, Demosky S, Thacker SG, Zazour A, Hornung RL, Pucino F, Csako G, Yarboro C, McInnes IB, Kuroiwa T, Boumpas D, Rao VK, Illei GG, **Remaley AT**. Elevated interleukin-10: A new cause of dyslipidemia leading to severe HDL deficiency. *J Clin Lipidol.* 2015 Jan-Feb;9(1):81-90
218. Gordon SM, McKenzie B, Kemeh G, Sampson M, Perl S, Young NS, Fessler MB, **Remaley AT**. Rosuvastatin Alters the Proteome of High Density Lipoproteins: Generation of Alpha-1-antitrypsin Enriched Particles with Anti-inflammatory Properties. *Mol Cell Proteomics.* 2015 Dec;14(12):3247-57.
219. Crossey E, Amar MJ, Sampson M, Peabody J, Schiller JT, Chackerian B, **Remaley AT**. A cholesterol-lowering VLP vaccine that targets PCSK9. *Vaccine.* 2015 Oct 26;33(43):5747-55.
220. Gourgari E, Lodish M, Shamburek R, Keil M, Wesley R, Walter M, Sampson M, Bernstein S, Khurana D, Lyssikatos C, Ten S, Dobs A, **Remaley AT**, Stratakis CA. Lipoprotein Particles in Adolescents and Young Women with PCOS Provide Insights into their Cardiovascular Risk. *J Clin Endocrinol Metab.* 2015 Nov;100(11):4291-8.
221. Lucero D, Svidirov D, Freeman L, López GI, Fassio E, **Remaley AT**, Schreier L. Increased Cholesterol Efflux Capacity in Metabolic Syndrome: Relation with Qualitative Alterations in HDL and LCAT. *Atherosclerosis.* 2015 Sep;242(1):236-42.
222. Jin X, Freeman SR, Vaisman B, Liu Y, Chang J, Varsano N, Addadi L, **Remaley A**, Kruth HS. ABCA1 Contributes to Macrophage Deposition of Extracellular Cholesterol. *J Lipid Res.* 2015 Sep;56(9):1720-6.
223. Hernáez Á, **Remaley AT**, Farràs M, Fernández-Castillejo S, Subirana I, Schröder H, Fernández-Mampel M, Muñoz-Aguayo D, Sampson M, Solà R, Farré M, de la Torre R, López-Sabater MC, Nyyssönen K, Zunft HJ, Covas MI, Fitó M. Olive Oil Polyphenols Decrease LDL Concentrations and LDL Atherogenicity in Men in a Randomized Controlled Trial. *J Nutr.* 2015 Aug;145(8):1692-7.
224. Schwendeman A, Sviridov DO, Yuan W, Guo Y, Morin EE, Yuan Y, Stonik J, Freeman L, Ossoli A, Thacker S, Killion S, Pryor M, Chen YE, Turner S, **Remaley AT**. The Effect of Phospholipid Composition of Reconstituted HDL on its Cholesterol Efflux and Anti-inflammatory Properties. *J Lipid Res.* 2015 Sep;56(9):1727-37.

225. Korzun WJ, Nilsson G, Bachmann LM, Myers GL, Sakurabayashi I, Nakajima K, Nakamura M, Shamburek RD, **Remaley AT**, Miller WG. Differences in bias approach for commutability assessment: application to frozen pools of human serum measured by 8 direct methods for HDL and LDL cholesterol. *Clin Chem*. 2015 Aug;61(8):1107-13.
226. Liu C, Gates KP, Fang L, Amar MJ, Schneider DA, Geng H, Huang W, Kim J, Pattison J, Zhang J, Witztum JL, **Remaley AT**, Dong PD, Miller YI. Apoc2 loss-of-function zebrafish mutant as a genetic model of hyperlipidemia. *Dis Model Mech*. 2015 Aug 1;8(8):989-98.
227. Thoreson CK, Chung ST, Ricks M, Reynolds JC, **Remaley AT**, Periwal V, Li Y, Sumner AE. Biochemical and clinical deficiency is uncommon in African immigrants despite a high prevalence of low vitamin D: the Africans in America study. *Osteoporos Int*. 2015 Nov;26(11):2607-15.
228. Thacker SG, Rousset X, Esmail S, Zarzour A, Jin X, Collins HL, Sampson M, Stonik J, Demosky S, Malide DA, Freeman L, Vaisman BL, Kruth HS, Adelman SJ, **Remaley AT**. Increased plasma cholesterol esterification by LCAT reduces diet-induced atherosclerosis in SR-BI knockout mice. *J Lipid Res*. 2015 Jul;56(7):1282-95.
229. Barochia AV, Kaler M, Cuento RA, Gordon EM, Weir NA, Sampson M, Fontana JR, MacDonald S, Moss J, Manganiello V, **Remaley AT**, Levine SJ. Serum apolipoprotein A-I and large high-density lipoprotein particles are positively correlated with FEV1 in atopic asthma. *Am J Respir Crit Care Med*. 2015 May 1;191(9):990-1000.
230. Schueler U, Kaneski C, **Remaley AT**, Demosky S, Dwyer N, Blanchette-Mackie J, Hanover J, Brady R. A Short Synthetic Peptide Mimetic of ApolipoproteinA-I Mediates Cholesterol and Globotriaosylceramide Efflux from Fabry Fibroblasts *JIMD Rep*. 2015;29:69-75.
231. de Messieres M, Ng A, Duarte CJ, **Remaley AT**, Lee JC. Single-Particle Tracking of Human Lipoproteins. *Anal Chem*. 2015;88(1):596-9.
232. Sakurai T, Sakurai A, Vaisman BL, Amar MJ, Liu C, Gordon SM, Drake SK, Pryor M, Sampson ML, Yang L, Freeman LA, **Remaley AT**. Creation of ApoC-II Mutant Mice and Correction of their Hypertriglyceridemia with an ApoC-II Mimetic Peptide. *J Pharmacol Exp Ther*. 2015;356(2):341-53.
233. Townsend K, Meissner EG, Sidharthan S, Sampson M, **Remaley AT**, Tang L, Kohli A, Osinusi A, Masur H, Kottlilil S. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration. *AIDS Res Hum Retroviruses*. 2015;32(5):456-62.
234. Ossoli A, **Remaley AT**, Vaisman B, Calabresi L, Gomaschi M. Plasma-derived and synthetic high density lipoproteins inhibit tissue factor in endothelial cells and monocytes. *Biochem J*. 2015;473(2):211-9.
235. Sampson ML, Gounden V, van Deventer HE, **Remaley AT**. CUSUM-Logistic Regression Analysis for the Rapid Detection of Errors in Clinical Laboratory Test Results. *Clin Biochem*. 2015;49(3):201-7.
236. Vaisman BL, Vishnyakova TG, Freeman LA, Amar MJ, Demosky SJ, Liu C, Stonik JA, Sampson ML, Pryor M, Bocharov AV, Eggerman TL, Patterson AP, **Remaley AT**. Endothelial Expression of Scavenger Receptor Class B, Type I Protects against Development of Atherosclerosis in Mice. *Biomed Res Int*. 2015;607120.doi:10.1155/607120. Epub
237. Shamburek RD, Bakker-Arkema R, Shamburek AM, Freeman LA, Amar M, Auerbach B, Krause BR, Homan R, Adelman SJ, Collins HL, Sampson M, Wolska A, **Remaley AT** Safety and Tolerability of ACP-501, a Recombinant Human Lecithin:Cholesterol Acyltransferase, in a Phase I Single-Dose Escalation Study. *Circ Res*. 2015;118(1):73-82.
238. Souza ACP, Bocharov AV, Baranova I, Vishnyakova T, Huang YG, Wilkins KJ, Hu X, Street JM, Alvarez-Prats A, Mullick AE, Patterson AP, **Remaley AT**, Eggerman TL, Yuen ST, Star RS, Antagonism of Scavenger Receptor CD36 by 5A Peptide Prevents Chronic Kidney Disease Progression in Mice Independent of Blood Pressure Regulation, *Kidney Int*. 2016;89(4):809-22.

239. Sviridov DO, Drake SK, Freeman LA, **Remaley AT**. Amphipathic polyproline peptides stimulate cholesterol efflux by the ABCA1 transporter. *Biochem Biophys Res Commun*. 2016 Mar 18;471(4):560-5.
240. Fernández-Castillejo S, Valls RM, Castañer O, Rubió L, Catalán Ú, Pedret A, Macià A, Sampson ML, Covas MI, Fitó M, Motilva MJ, **Remaley AT**, Solà R. Polyphenol rich olive oils improve lipoprotein particle atherogenic ratios and subclass profile: A randomized, crossover, controlled trial. *Mol Nutr Food Res*. 2016 Jul;60(7):1544-54.
241. Shamburek RD, Bakker-Arkema R, Auerbach BJ, Krause BR, Homan R, Amar MJ, Freeman LA, and **Remaley AT**. Familial Lecithin:Cholesterol Acyltransferase Deficiency: First-in-Human Treatment with Enzyme Replacement. *J Clinical Lipidol*. 2016;10(2)356-67.
242. Kang JG, Sung HJ, Amar MJ, Pryor M, **Remaley AT**, Allen MD, Noguchi AC, Springer DA, Kwon J, Chen J, Park JH, Wang PY, Hwang PM. Low ambient oxygen prevents atherosclerosis. *J Mol Med (Berl)*. 2016 Mar;94(3):277-86.
243. Hsieh MM, Callacondo D, Rojas-Camayo J, Quesada-Olarte J, Wang X, Uchida N, Maric I, **Remaley AT**, Leon-Velarde F, Villafuerte FC, Tisdale JF. SENP1, but not fetal hemoglobin, differentiates Andean highlanders with chronic mountain sickness from healthy individuals among Andean highlanders. *Exp Hematol*. 2016 Jun;44(6):483-490.
244. Bevans MF, Ross A, Wehrle L, Klagholz SD, Yang L, Childs R, Flynn SL, **Remaley AT**, Krumlauf M, Reger RN, Wallen GR, Shamburek R, Pacak K. Documenting stress in caregivers of transplantation patients: Initial evidence of HPA dysregulation. *Stress*. 2016;19(2):175-84.
245. Baranova IN, Souza AC, Bocharov AV, Vishnyakova TG, Hu X, Vaisman BL, Amar MJ, Chen Z, Kost Y, **Remaley AT**, Patterson AP, Yuen PS, Star RA, Eggerman TL. Human SR-BI and SR-BII potential LPS-induced inflammation and acute liver and kidney injury in mice. *J Immunol*. 2016 Apr 1;196(7):3135-47.
246. Baranova IN, Souza ACP, Bocharov AV, Vishnyakova TG, Hu X, Vaisman BL, Amar MJ, Chen Z, **Remaley AT**, Patterson AP, Yuen PST, Star RA, Eggerman TL. Human SR-BII mediates SAA uptake and contributes to SSA pro-inflammatory signaling in vitro and in vivo. *PLoS One*. 2017 Apr 19;12(4):e0175824. doi: 10.1371
247. Jorissen W, Wouters E, Bogie JF, Vanmierlo T, Noben JP, Sviridov D, Hellings N, Somers V, Valcke R, Vanwijmeersch B, Stinissen P, Mulder MT, **Remaley AT**, Hendriks JJ. Relapsing-remitting multiple sclerosis patients display an altered lipoprotein profile with dysfunctional HDL. *Sci Rep*. 2017 Feb 23;7:43410.
248. Sakurai T, Sakurai A, Chen Y, Vaisman BL, Amar MJ, Pryor M, Thacker SG, Zhang X, Wang X, Zhang Y, Zhu J, Yang ZH, Freeman LA, **Remaley AT**. Dietary alpha-cyclodextrin reduces atherosclerosis and modifies gut flora in apoE-deficient mice. *Mol Nutr Food Res*. 2017 Jan 19. doi: 10.1002/mnfr.201600804. [Epub ahead of print]
249. Gordon SM, Pourmousa M, Sampson M, Sviridov D, Islam R, Perrin BS Jr, Kemeh G, Pastor RW, **Remaley AT**. Identification of a novel lipid binding motif in ApoB by the analysis of hydrophobic cluster domains. *Biochim Biophys Acta*. 2017 Feb;1859(2):135-145.
250. Jin X, Sviridov D, Liu Y, Vaisman B, Addadi L, **Remaley AT**, Kruth HS. ABCA1 mediates ApoA-I and ApoA-I mimetic peptide mobilization of extracellular cholesterol microdomains deposited by macrophages. *Arterioscler Thromb Vasc Biol*. 2016 Dec;36(12):2283-2291.
251. Yang X, Sethi A, Yanek LR, Knapper C, Nordestgaard BG, Tybjaerg-Hansen A, Becker DM, Mathias RA, **Remaley AT**, Becker LC. SCARB1 gene variants are associated with the phenotype of combined high HDL-C and high Lipoprotein (a). *Circ Cardiovasc Genet*. 2016 Oct;9(5):408-418.
252. Armenian SH, Chemaitilly W, Chen M, Chow EJ, Duncan CN, Jones LW, Pulsipher MA, **Remaley AT**, Rovo A, Salooja N, Battiwalla M. NIH hematopoietic cell transplantation late effects initiative: The

- cardiovascular disease and associated risk factors working group report. *Biol Blood Marrow Transplant*. 2017 Feb;23(2):201-210.
253. Joshi AA, Lerman JB, Aberra TM, Afshar M, Teague HL, Rodante JA, Krishnamoorthy P, Ng Q, Aridi TZ, Salahuddin T, Natarajan B, Lockshin BN, Ahlman MA, Chen MY, Rader DJ, Reilly MP, **Remaley AT**, Bluemke DA, Playford MP, Gelfand JM, Mehta NN. GlycA is a novel biomarker of inflammation and subclinical cardiovascular disease in psoriasis. *Circ Res*. 2016 Nov 11;119(11):1242-1253.
254. Sorokin AV, Yang ZH, Vaisman BL, Thacker S, Yu ZX, Sampson M, Serhan CN, **Remaley AT**. Addition of aspirin to a fish oil-rich diet decreases inflammation and atherosclerosis in apoE-null mice. *J Nutr Biochem*. 2016 Sep;35:58-65.
255. Ossoli A, Neufeld EB, Thacker SG, Vaisman B, Pryor M, Freeman LA, Brantner CA, Baranova I, Francone NO, Demosky SJ Jr, Vitali C, Locatelli M, Abbate M, Zoja C, Franceschini G, Calabresi L, **Remaley AT**. Lipoprotein X causes renal disease in LCAT deficiency. *PLoS One*. 2016 Feb 26;11(2):e0150083.
256. Thacker SG, Zarzour A, Chen Y, Alciçek MS, Freeman LA, Sviridov DO, Demosky SJ Jr, **Remaley AT**. HDL reduces inflammation from cholesterol crystals by inhibiting inflammasome activation. *Immunology*. 2016 Nov;149(3):306-319.
257. Sano O, Tsujita M, Shimizu Y, Kato R, Kobayashi A, Kioka N, **Remaley AT**, Michikawa M, Ueda K, Matsuo M. ABCG1 and ABCG4 suppress gamma-secretase activity and amyloid production. *PLoS One*. 2016 May 19;11(5):e0155400. doi: 10.1371/journal.pone.0155400.
258. Amar MJ, Kaler M, Courville AB, Shamburek R, Sampson M, **Remaley AT**. Randomized double blind clinical trial on the effect of oral alpha-cyclodextrin on serum lipids. *Lipids Health Dis*. 2016 Jul 12;15(1):115. doi: 10.1186/s12944-016-0284-6
259. Furumoto Y, Smith CK, Blanco L, Zhao W, Brooks SR, Thacker SG, Zarzour A, Sciumè G, Tsai WL, Trier AM, Nunez L, Mast L, Hoffmann V, **Remaley AT**, O'Shea JJ, Kaplan MJ, Gadina M. Tofacitinib ameliorates murine lupus and its associated vascular dysfunction. *Arthritis Rheumatol*. 2017 Jan;69(1):148-160.
260. Nowacki TM, **Remaley AT**, Bettenworth D, Eisenblätter M, Vowinkel T, Becker F, Vogl T, Roth J, Tietge UJ, Lügering A, Heidemann J, Nofer JR. the 5A apoA-I mimetic peptide ameliorates experimental colitis by regulating monocyte infiltration. *Br J Pharmacol*. 2016 Sep;173(18):2780-92.
261. Ahmad F, Chung YW, Tang Y, Hockman SC, Liu S, Khan Y, Huo K, Billings E, Amar MJ, **Remaley AT**, Manganiello VC. Phosphodiesterase 3B regulates NLRP3 inflammasome in adipose tissue. *Sci Rep*. 2016 Jun 20;6:28056. doi: 10.1038/srep28056
262. Bocharov AV, Wu T, Baranova IN, Birukova AA, Sviridov D, Vishnyakova TG, **Remaley AT**, Eggerman TL, Patterson AP, Birukov KG. Synthetic amphipathic helical peptides targeting CD36 attenuate LPS induced inflammation and acute lung injury. *J Immunol*. 2016 Jul 15;197(2):611-9.
263. Bradbury A, Bagel J, Sampson M, Farhat N, Ding W, Swain G, Prociuk M, O'Donnell P, Drobatz K, Gurda B, Wassif C, **Remaley A**, Porter F, Vite C. Cerebrospinal fluid calbindin concentration as a biomarker of cerebellar disease progression in Niemann-Pick type C1 disease. *J Pharmacol Exp Ther*. 2016 Aug;358(2):254-61.
264. Jee YH, Sadowski SM, Celi FS, Xi L, Raffeld M, Sacks DB, **Remaley AT**, Wellstein A, Kebebew E, Baron J. Increased pleiotrophin concentrations in papillary thyroid cancer. *PLoS One*. 2016 Feb 25;11(2):e0149383.
265. Yang ZH, Bando M, Sakurai T, Chen Y, Emma-Okon B, Wilhite B, Fukuda D, Vaisman B, Pryor M, Wakabayashi Y, Sampson M, Yu ZX, Sakurai A, Zarzour A, Miyahara H, Takeo J, Sakaue H, Sata M, **Remaley AT**. Long-chain monounsaturated fatty acid-rich fish oil attenuates the development of atherosclerosis in mouse models. *Mol Nutr Food Res*. 2016 Oct;60(10):2208-2218.
266. Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, Watts GF, Sypniewska G, Wiklund O, Borén J, Chapman MJ, Cobbaert C, Descamps OS, von Eckardstein A, Kamstrup PR, Pulkki K, Kronenberg F, **Remaley AT**, Rifai N, Ros E, Langlois M; European Atherosclerosis Society (EAS) and the

European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) joint consensus initiative. Fasting is not routinely required for determination of a lipid profile. *Eur Heart J.* 2016 Jul 1;37(25):1944-58.

267. Ueda M, Dunbar RL, Wolska A, Sikora TU, Escobar MD, Seliktar N, deGoma E, DerOhannessian S, Morrell L, McIntyre AD, Burke F, Sviridov D, Amar M, Shamburek RD, Freeman L, Hegele RA, **Remaley AT**, Rader DJ. A novel ApoC2 missense mutation causing apolipoprotein C-II deficiency with severe triglyceridemia and pancreatitis. *J Clin Endocrinol Metab.* 2017 Feb 13.

Reviews

1. Glew, R.H.; Basu, A.; Prence, E.M.; **Remaley, A.T.**: Biology of Disease: Lysosomal Storage Diseases. *Lab. Invest.* 53:250-269, 1985.
2. Glew, R.H.; Saha, A.K.; **Remaley, A.T.**; Das, S.: Biochemistry of Leishmania. *Microbiol. Reviews*, 52:412-32, 1988
3. **Remaley, A.T.**; Wilding, P.: Macroeozymes: Biochemical Characterization, Clinical Significance, and Laboratory Detection. *Clin. Chem.*,35:2261-70, 1990
4. **Remaley A.T.**; Woods J.W.; Glickman J.W.: Point-of-care Testing of Parathyroid Hormone During the Surgical Treatment of Hyperparathyroidism. *Medical Laboratory Observer* 31: 20-7, 1999
5. GR Warnick, **Remaley AT**. Measurement of cholesterol in plasma and other body fluids. *Current Atherosclerosis Reports* Sep;3(5):404-11, 2001
6. Sokoll LJ, Wians Jr FH, **Remaley AT**. Rapid Intraoperative Immunoassay of Parathyroid Hormone and Other Hormones: A New Paradigm for Point-of-Care Testing. *Clin Chem.* 2004 Jul;50(7):1126-35
7. Brewer HB Jr, **Remaley AT**, Neufeld EB, Basso F, Joyce C. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. *Arterioscler Thromb Vasc Biol.* 2004 Oct;24(10):1755-60.
8. Nofer JR, **Remaley AT**. Tangier disease: Still more questions than answers. *Cell Mol Life Sci.* 2005 Oct;62(19-20):2150-60.
9. Ueda, M., Sethi, AA., Freeman, LA., Vaisman, BL., Amar, M., Shamburek, RD, **Remaley, AT**. High Density Lipoproteins: Overview and Update on New Findings from Diagnostics to Therapeutics. *J Clinical Ligand Assay* 2006;28(4):216-32.
10. Reddy V, Khan AI, **Remaley AT**, Wians FH. Update on Point-of-Surgery Testing. *Lab Med.* 2006;37:754-6.
11. Sethi A, Amar M, Shamburek RD, **Remaley AT**. Apolipoprotein AI mimetic peptides: Possible new agents for the treatment of atherosclerosis. *Curr Opinion in Invest Drugs.* 2007 Mar;8(3):201-12.
12. **Remaley AT**. Old Drug, New Tricks: The unexpected effect of doxazosin on high-density lipoprotein. *Circ. Res.* 2007 Jul 20;101(2):116-8.
13. **Remaley AT**, Warnick GR. High Density Lipoprotein: What is the best way to measure its anti-atherogenic potential? *Expert Opinion in Medical Diagnostics.* 2008; 2(7):773-788
14. Sviridov D, Mukhamedova N, **Remaley AT**, Chin-Dusting J, Nestel P. Antiatherogenic functionality of high density lipoprotein: how much versus how good. *J Atheroscler Thromb.* 2008 Apr;15(2):52-62.
15. **Remaley AT**, Amar M, Sviridov D. HDL Replacement Therapy: Mechanism of action, types of agents and potential clinical indicators. *Expert Rev in Cardiovasc Ther.* 2008 Oct;6(9):1203-15.

16. Rousset X, Vaisman B, Amar M, Sethi AA, **Remaley AT**. Lecithin: cholesterol acyltransferase—from biochemistry to role in cardiovascular disease. *Curr Opin Endocrinol Diabetes Obes*. 2009 Apr;16(2):163-71.
17. Murphy AJ, **Remaley AT**, Sviridov D. HDL Therapy: Two kinds of right? *Curr Pharm Des*. 2010;16:4134-47.
18. Vickers KC, **Remaley AT**. MicroRNAs in atherosclerosis and lipoprotein metabolism. *Curr Opin Endocrinol Diabetes Obes*. 2010 April; 17(2) 150-55.
19. Rousset X, Shamburek R, Vaisman B, Amar M, **Remaley AT**. Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor? *Curr Atheroscler Rep*. 2011;13(3):249-56.
20. **Remaley AT**. "Who's on first": Determining the roster for the key players in the reverse cholesterol transport pathway. *Athero* 2011;218(2):287-9.
21. Yao X, **Remaley AT**, Levine SJ. New kids on the block: The emerging role of apolipoproteins in the pathogenesis of asthma. *Chest* 2011 140:1048-54.
22. Osei-Hwedieh DO, Amar M, Sviridov D, **Remaley AT**. Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents. *Pharmacol Ther*. 2011 Apr;130(1):83-91.
23. Yao, X, Vitek MP, **Remaley AT**. Levine SJ. Apolipoprotein Mimetic peptides: A new approach for the treatment of asthma. *Front. Pharmacol*. 2012;3:37-45.
24. Rosenson RS, Brewer HB, Davidson WS, Zahi A, Fayad, Valentin Fuster, James Goldstein, Marc Hellerstein, Xian-Cheng Jiang, Michael C. Phillips, **Remaley AT**, Daniel J. Rader, George H. Rothblat, Alan R. Tall, Laurent Yvan-Charvet. Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport. *Circulation* 2012 Apr 17; 125 (15): 1905-19.
25. Vickers KC, **Remaley AT**. Lipid-based carriers of microRNAs and intercellular communication. *Curr Opin Lipidol* 2012 23:91-7
26. Krause BR, **Remaley AT**. Reconstituted HDL for the acute treatment of acute coronary syndrome. *Curr Opin Lipidol*. 2013;24:480-6.
27. Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, **Remaley AT**. High-Density lipoprotein and prostate cancer: An overview. *J Epidemiology* 2013;23:313-9.
28. Vickers KC, Sethupathy P, Baran-Gale J, **Remaley AT**. Complexity of microRNA function and the role of isomiRs in lipid homeostasis. *J Lipid Res* 2013;54:1182.
29. Vickers KC, **Remaley AT**. HDL and cholesterol: Life after the divorce? *J Lipid Res* 2013: 55:4.
30. **Remaley AT**, Shamburek RD, Amar M. The new ACC/AH cardiovascular risk guidelines: impact and controversies. *Clin Chem*. 2014 Nov;60(11):1365-7.
31. **Remaley AT**, Norata GD, Catapano AL. Novel concepts in HDL pharmacology. *Cardiovasc Res*. 2014 Aug 1;103(3):423-8.
32. Brown WV, **Remaley AT**, Ridker PM. JCL Rountable: Is inflammation a future target in preventing atherosclerotic cardiovascular disease. *J Clin Lipidol*. 2015 Mar-Apr;9(2):119-28.
33. Sviridov D, **Remaley AT**. High-density lipoprotein mimetics: promises and challenges. *Biochem J*. 2015 Dec 15;472(3):249-59.
34. Sorokin AV, Yang Z-H, **Remaley AT**. Anti-inflammatory and atheroprotective properties of Omega-3 Polyunsaturated fatty acids. *J Clin & Exp Cardiol*. 2016;7:1 DOI: 10.4172/2155-980.1000478.
35. Yang ZH, Emma-Okon B, **Remaley AT**. Dietary marine-derived long-chain monounsaturated fatty acids and cardiovascular disease risk: A mini review. *Lipids Health Dis*. 2016 Nov 22;15(1):201.

36. Sandhu PK, Musaad SM, Remaley AT, Buehler SS, Strider S, Derzon JH, Vesper HW, Ranne A, Shaw CS, Christenson RH. Lipoprotein biomarkers and risk of cardiovascular disease: A laboratory medicine best practices systematic review. *J Appl Lab Med*. 2016 Sep 1;1(2):214-229.
37. Pavlatou MG, **Remaley AT**, Gold PW. Klotho: A humoral mediator in CSF and plasma that influences longevity and susceptibility to multiple complex disorders, including depression. *Transl Psychiatry*. 2016 Aug 30;6(8):e876. doi: 10.1038/tp.2016.135.
38. Yao X, Gordon EM, Barochia AV, **Remaley AT**, Levine SJ. The A's have it: Developing ApoA-I mimetic peptides into a novel treatment for asthma. *Chest*. 2016 Aug;150(2):283-8.
39. Chackerian B, **Remaley A**. Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin/kexin type 9. *Curr Opin Lipidol*. 2016 Aug;27(4):345-50.
40. Brown WV, Moriarty PM, **Remaley AT**, Tsimikas S. JCL Roundtable: Should we treat elevations in Lp(a)? *J Clin Lipidol*. 2016 Mar-Apr;10(2):215-24.
41. Gordon SM, **Remaley AT**. High Density lipoproteins are modulators of protease activity: Implications in inflammation, complement activation and atherothrombosis. *Atherosclerosis* 2017;259:104-113.
42. Karathanasis SK, Freeman LA, Gordon SM, **Remaley AT**. The changing face of HDL and the best way to measure it. *Clin Chem*. 2017 Jan;63(1):196-210.

Book Chapters

1. Campbell, I.M.; Bartman, C.D.; Doerfler, D.L.; Bird, B.A.; **Remaley, A.T.**: *The Role of Secondary Metabolism in Penicillium brevicompactum*. In: *Advances in Biotechnology*. M. Moo-Young, C. Vezina and K. Singh (Eds.), Pergamon, Toronto. Chapter 3, pp. 9-14, 1981.
2. **Remaley, A.T.**; and LaMarco, K.L.: *Phenylketonuria: A Dihydropteridine Reductase Deficiency*. In: *Clinical Studies in Medical Biochemistry*. R.H. Glew and S.P. Peters (Eds.), Oxford University Press, 1987: pp. 147-154
3. Hoeg, J.M.; **Remaley, A.T.**: *Reverse Cholesterol Transport*. In: *Genetic Factors in Heart Disease*. U. Goldbourt, U. deFaire and K. Berg (Eds.), Kluwer Academic Publishers, 1994 pp. 351-372
4. **Remaley, A.T.**; Schumacher, U.K.; Brewer, H.B.; Hoeg, J.M.: *Isolation of Novel Genes Regulated by Dietary Cholesterol by a PCR-based Subtraction Library*. In: *Cardiovascular Disease 2*. L.L. Gallo (Ed.), Plenum Press. 1995: pp. 327-332
5. **Remaley, A.T.**: *Phenylketonuria: Biochemical Basis of a Clinically Heterogenous Disorder*. In: *Clinical Studies in Medical Biochemistry*. R.H. Glew (Ed.), Oxford University Press, 1997: pp. 302-309
6. **Remaley, A.T.**: *Abetalipoproteinemia: A Disorder of Lipoprotein Assembly*. In: *Clinical Studies in Medical Biochemistry*. R.H. Glew (Ed.), Oxford University Press, 1997: pp. 195-201
7. **Remaley AT**, McNamara JR, Warnick GR. *Lipids and Lipoproteins*. In: Bishop ML, Fody EP, Schoeff L (eds), *Clinical Chemistry, Principles, Procedures, Correlations*, Fifth Edition, pp. 282-313, Philadelphia, PA. Lippincott Williams & Wilkins, 2005.
8. **Hortin GL, Remley AT**. *Introduction to Protein Analysis*. In: Detrick B, Hamilton RG, Folds JD (eds), *Manual of Molecular and Clinical Laboratory Immunology*. 7th Edition, pp. 4-6, Washington, D.C., ASM Press, 2006

9. Hortin GL, **Remaley AT**. *Protein Analysis for Diagnostic Applications*. In: Detrick B, Hamilton RG, Folds JD (eds), *Manual of Molecular and Clinical Laboratory Immunology*. 7th Edition, pp. 4-6, Washington, D.C., ASM Press, 2006
8. Bowen RA, **Remaley AT** *Hypoalphalipoproteinemia*. In *Tietz's Applied Laboratory Medicine*, John Wiley&Sons, Inc. 2007, pp. 581-584.
9. Shamburek R, **Remaley AT** *Sitosterolemia*, In *Tietz's Applied Laboratory Medicine*, John Wiley&Sons, Inc. 2007, pp. 589-592.
10. Ueda M, **Remaley AT**. *Hyperbetalipoproteinemia*, In *Tietz's Applied Laboratory Medicine*, John Wiley&Sons, Inc. 2007, pp. 585-588.
11. Jialal I, **Remaley AT**. *Laboratory Diagnosis of Lipoprotein Disorders*, In *Handbook of Diagnostic Endocrinology*, AACC Press 2008, pp. 323-340
12. Raffick B, **Remaley AT**. *Identification and Resolution of Immunoassay Interferences*, In *Handbook of Diagnostic Endocrinology*, AACC Press 2008. Pp. 1-24
13. Rifai N, Warnick R **Remaley AT**. *Lipids, Lipoproteins, and other Cardiovascular Risk Markers*. In *Tietz's Fundamentals of Clinical Chemistry*, Sixth Edition, John Wiley&Sons, Inc. 2007, pp. 402-430
14. Sethi A, Warnick GR, **Remaley AT** *Lipids and Lipoproteins*. In: Bishop ML, Fody EP, Schoeff L (eds), *Clinical Chemistry, Principles, Procedures, Correlations*, Sixth Edition, Philadelphia, PA. Lippincott Williams & Wilkins, 2010, pp. 328-355
15. **Remaley AT**, Shamburek RD, Disorders of Lipid and Lipoprotein Metabolism. In: Dietzen DJ, Bennet MJ, Wong ECC (eds), *Biochemical and Molecular Basis of Pediatric Disease*, Fourth Edition, AACC Press, 2010, pp. 503-530.
16. **Remaley AT**, Rifai N, Warnick GR. Lipids, Lipoproteins, Apolipoproteins, and other Cardiovascular Risk Factors, In *Tietz Clinical Chemistry and Molecular Diagnostics*, Elsevier, Inc. 2011, pp. 731-805
17. **Remaley AT**, Murray PR, Fleisher TA. Integration of Specialized Research Services into Clinical Laboratory Operations, In *Principles and Practice of Clinical Research*. Elsevier, 2012 (In Press).
18. **Remaley AT**, Rifai N, Warnick. *Lipids, Lipoproteins, and other Cardiovascular Risk Markers*. In *Tietz's Fundamentals of Clinical Chemistry*, Seventh Edition, John Wiley&Sons, Inc., 2012 (In Press).
19. Raffick B, Sethi A, Warnick GR, **Remaley AT** *Lipids and Lipoproteins*. In: Bishop ML, Fody EP, Schoeff L (eds), *Clinical Chemistry, Principles, Procedures, Correlations*, Seventh Edition, Philadelphia, PA. Lippincott Williams & Wilkins, 2012 (In Press).
20. Ahsan L, Ossoli AF, Freeman L, Vaisman B, Amar BV, Shamburek R, and **Remaley AT**. Role of Lecithin: Cholesterol Acyltransferase in HDL Metabolism and Atherosclerosis. In: *HDL Handbook*, 2nd edition, Elsevier Inc., 2013, pp. 159-194.
21. Li D, Gordon S, Schwendeman, **Remaley AT**. Apolipoprotein Mimetic Peptides for Stimulating Cholesterol Efflux. In: *Apolipoprotein Mimetics in the Management of Human Disease*. Springer Cham Heidelberg, 2015, pp. 29-42.
22. Freeman, LA and **Remaley, AT**. Discovery of High Density Lipoprotein Gene Targets from Classical Genetics to Genome Wide Association Studies. In "Translational Cardiometabolic Genomic Medicine," 2016, pp. 119-159, Annabelle Rodriguez, Editor. Elsevier, Oxford, U.K.
23. **Remaley AT**, Dayspring T, Warnick GR. Lipids, Lipoproteins, Apolipoproteins, and other Cardiovascular Risk Factors, In *Tietz Clinical Chemistry and Molecular Diagnostics*, Elsevier, Inc. 2017, Sixth Edition, pp. 539-603.

Newsletters/Editorials/Book Reviews/Commentaries

1. **Remaley AT.** Tangier disease and new concepts in the reverse cholesterol transport pathway. AACC, Lipoproteins and Vascular Disease Newsletter 1988;12(2):1-8
2. **Remaley AT.** Chair's Corner. AACC, Lipoproteins and Vascular Disease Newsletter 2003;16(1):3-4
3. **Remaley AT.** ABC transporters in genetic disorders of cholesterol metabolism. AACC, Lipoproteins and Vascular Disease Newsletter 2003;16(2):7-12
4. **Remaley AT.** Chair's Corner. AACC, Lipoproteins and Vascular Disease Newsletter 2003;16(3):3-4
5. **Remaley AT.** Book Review of "Proteomic and Genomic Analysis of Cardiovascular Disease. Jennifer E. Van Eyk and Michael J. Dunn (ed). Weinheim, Federal Republic of Germany: Wiley-VCH Verlag GmbH & Co". Clin Chem 2003.
6. **Remaley AT.** Chair's Corner. AACC, Lipoproteins and Vascular Disease Newsletter 2003;16(4):3-4
7. **Remaley AT.** Potential new treatment strategies for raising HDL. AACC, Lipoproteins and Vascular Disease Newsletter 2006;20(2):14-18
8. **Remaley AT.** Book Review of "Proteomic and Genomic Analysis of Cardiovascular Disease. Jennifer E. Van Eyk and Michael J. Dunn (ed). Weinheim, Federal Republic of Germany: Wiley-VCH Verlag GmbH & Co". Clin Chem 2003.
9. **Remaley AT.** Book Review of "Lipids and Atherosclerosis (Advances in Translational Medical Science). Abingdon, Oxon, United Kingdom: Taylor & Francis Group, 2006" Clin Chem, 2006.
10. Warnick R, **Remaley AT**, Boggess C, Mallory T, Chao-Shern C. Lipoprotein Subclasses in Cardiovascular Risk Assessment and Patient Management. Analysis of lipoprotein subclasses can improve cardiovascular risk assessment and patient management. Clin Lab Int Review 2007: Sept.
11. **Remaley AT**, Warnick R. HDL-C: The changing testing paradigm-Part I. Clin Lab News 2007;33(11):10-12
12. **Remaley AT**, Warnick R. HDL-C: The changing testing paradigm-Part II. Clin Lab News 2007;33(11):8-11
13. **Remaley AT**, Commentary on "An unusual case of severe hypertriglyceridemia and splenomegaly". Clin Chem 2008; 54:610-611.
14. **Remaley AT.** Book Review of "Lipids and Atherosclerosis (Advances in Translational Medical Science). Abingdon, Oxon, United Kingdom: Taylor & Francis Group, 2006" Clin Chem, 2006.
15. Jim DeLeo, **Alan T. Remaley**, G. William Moore, and Gerald L. McLaughlin NIH Biomedical Computing Interest Group Book Club Review of "Outliers: The Story of Success" by Malcolm Gladwell. Clin Chem, 2009.
16. **Remaley AT.** Website Review for Directus: A portal for CME approved self-directed learning. Clin Chem, 2009.
17. Kara L. Kuntz-Melcavage, Ellen Bicknell, Jim DeLeo, Rick Hansen, Gerald McLaughlin, G. William Moore, and **Alan T Remaley** Book NIH Biomedical Computing Interest Group Book Club Review of How Doctors Think by Jerome Groopman. Clin Chem, 2009
18. Jim DeLeo, **Alan T Remaley**, G. William Moore, Gerald L McLaughlin, Ellen J Bicknell, and Melanie Swan Book Review of "The Pig That Wants to be Eaten: 100 Experiments for the Armchair Philosopher " Clin Chem, 2009

19. **Remaley AT**, Palmer-Toy D. C-reactive protein (CRP) as a Cardiovascular Risk Marker, College of American Pathology Education Supplement. C-C Nov. 2010
20. **Remaley AT**, Baltaro RJ. Pediatric Lipid Screening for Cardiovascular Disease, College of American Pathology Education Supplement. CR-B Nov. 2012
21. **Remaley AT**, Commentary on "An unusual case of hypobetalipoproteinemia". Clin Chem 2012;58:830.
22. **Remaley AT**, Commentary on "A 54-year-old man with low serum cholesterol". Clin Chem 2012. (In Press).
23. Cole RG, Contois JH, Csako G, McConnell JP, **Remaley AT**, Devaraj S, Hoefner DM, Mallory T, Sethi AA, Warnick GR. In Reply. Clin Chem 2013;59:1277-8.
24. **Remaley AT**, Response to question on need to fast for lipid tests. CAP Today 2013;27:100-1.
25. Bowen RA, **Remaley AT**. Interferences from blood collection tube components on clinical chemistry assays. Biochem Med (Zagreb). 2014 Feb 15;24(1):31-44.
26. **Remaley AT**. Tomatoes, lysophosphatidic acid, and the small intestine: New pieces in the puzzle of apolipoprotein mimetic peptides? J Lipid Res. 2013 Dec;54(12):3223-6.
27. **Remaley AT**. Apolipoprotein A-II: Still second fiddle in high-density lipoprotein metabolism? Arterioscler Thromb Vasc Biol 2013; 33:166-67.
28. **Remaley AT**. Commentary on Case Report of a Patient with High Triglycerides and Low HDL-C. Clin Chem. 2015 Dec;61(12):1444-5.
29. **Remaley AT**. Commentary on Case Report of Patient with Elevated Lp(X) particles. Clin Chem. 2015 Aug;61(8):1032.
30. **Remaley AT**. Commentary on Case Report of Patient with Low HDL. Clin Chem. 2017 Mar;63(3):645
31. Wolska A, **Remaley AT**. Lipoprotein Subfraction Analysis: The continuing quest for improving cardiovascular risk prediction. Clin Laboratory News. Jan. 2017: 17-20.